An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention.
Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells.
An angiotensin receptor subtype that is expressed at high levels in fetal tissues. Many effects of the angiotensin type 2 receptor such as VASODILATION and sodium loss are the opposite of that of the ANGIOTENSIN TYPE 1 RECEPTOR.
A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.
A heptapeptide formed from ANGIOTENSIN II after the removal of an amino acid at the N-terminal by AMINOPEPTIDASE A. Angiotensin III has the same efficacy as ANGIOTENSIN II in promoting ALDOSTERONE secretion and modifying renal blood flow, but less vasopressor activity (about 40%).
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM.
A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992) EC 3.4.15.1.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19.
Agents that antagonize the ANGIOTENSIN II TYPE 2 RECEPTOR.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.
Oligopeptides which are important in the regulation of blood pressure (VASOCONSTRICTION) and fluid homeostasis via the RENIN-ANGIOTENSIN SYSTEM. These include angiotensins derived naturally from precursor ANGIOTENSINOGEN, and those synthesized.
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
The active metabolite of ENALAPRIL and a potent intravenously administered angiotensin-converting enzyme inhibitor. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.
An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION.
A synthetic nonapeptide (Pyr-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) which is identical to the peptide from the venom of the snake, Bothrops jararaca. It inhibits kininase II and ANGIOTENSIN I and has been proposed as an antihypertensive agent.
An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.
Compounds with a BENZENE fused to IMIDAZOLES.
One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors) used for hypertension. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
An ANGIOTENSIN II analog which acts as a highly specific inhibitor of ANGIOTENSIN TYPE 1 RECEPTOR.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.
A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter.
Drugs used to cause constriction of the blood vessels.
A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke.
Agents that promote the excretion of urine through their effects on kidney function.
An alpha-globulin of about 453 amino acids, depending on the species. It is produced by the liver and secreted into blood circulation. Angiotensinogen is the inactive precursor of natural angiotensins. Upon successive enzyme cleavages, angiotensinogen yields angiotensin I, II, and III with amino acids numbered at 10, 8, and 7, respectively.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
A group of ISOQUINOLINES in which the nitrogen containing ring is protonated. They derive from the non-enzymatic Pictet-Spengler condensation of CATECHOLAMINES with ALDEHYDES.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
Compounds based on reduced IMIDAZOLINES which contain no double bonds in the ring.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR).
Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.
An inhibitor of glutamate decarboxylase. It decreases the GAMMA-AMINOBUTYRIC ACID concentration in the brain, thereby causing convulsions.
A generic term used to describe a group of polypeptides with related chemical structures and pharmacological properties that are widely distributed in nature. These peptides are AUTACOIDS that act locally to produce pain, vasodilatation, increased vascular permeability, and the synthesis of prostaglandins. Thus, they comprise a subset of the large number of mediators that contribute to the inflammatory response. (From Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 8th ed, p588)
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.
Therapy with two or more separate preparations given for a combined effect.
A direct-acting vasodilator that is used as an antihypertensive agent.
A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
The circulation of the BLOOD through the vessels of the KIDNEY.
A phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.
Cell surface receptors that bind BRADYKININ and related KININS with high affinity and trigger intracellular changes which influence the behavior of cells. The identified receptor types (B-1 and B-2, or BK-1 and BK-2) recognize endogenous KALLIDIN; t-kinins; and certain bradykinin fragments as well as bradykinin itself.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
The nonstriated involuntary muscle tissue of blood vessels.
Elements of limited time intervals, contributing to particular results or situations.
The octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction.
Hypertension due to RENAL ARTERY OBSTRUCTION or compression.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure.
A diet which contains very little sodium chloride. It is prescribed by some for hypertension and for edematous states. (Dorland, 27th ed)
Peptides composed of between two and twelve amino acids.
The number of times the HEART VENTRICLES contract per unit of time, usually per minute.
Drugs that bind to and block the activation of MINERALOCORTICOID RECEPTORS by MINERALOCORTICOIDS such as ALDOSTERONE.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
The main trunk of the systemic arteries.
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)
A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation.
Excision of kidney.
Pathological processes of the KIDNEY or its component tissues.
A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
A constitutively expressed subtype of bradykinin receptor that may play a role in the acute phase of the inflammatory and pain response. It has high specificity for intact forms of BRADYKININ and KALLIDIN. The receptor is coupled to G-PROTEIN, GQ-G11 ALPHA FAMILY and G-PROTEIN, GI-GO ALPHA FAMILY signaling proteins.
The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
The consumption of liquids.
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Compounds with BENZENE fused to AZEPINES.
A cluster of convoluted capillaries beginning at each nephric tubule in the kidney and held together by connective tissue.
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
Compounds based on fumaric acid.
The thoracolumbar division of the autonomic nervous system. Sympathetic preganglionic fibers originate in neurons of the intermediolateral column of the spinal cord and project to the paravertebral and prevertebral ganglia, which in turn project to target organs. The sympathetic nervous system mediates the body's response to stressful situations, i.e., the fight or flight reactions. It often acts reciprocally to the parasympathetic system.
A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.
A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP.
The hollow, muscular organ that maintains the circulation of the blood.
Peptides composed of two amino acid units.
Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.
A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)
The measurement of an organ in volume, mass, or heaviness.
The portion of the descending aorta proceeding from the arch of the aorta and extending to the DIAPHRAGM, eventually connecting to the ABDOMINAL AORTA.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE.
A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
Sodium or sodium compounds used in foods or as a food. The most frequently used compounds are sodium chloride or sodium glutamate.
21-Amino-acid peptides produced by vascular endothelial cells and functioning as potent vasoconstrictors. The endothelin family consists of three members, ENDOTHELIN-1; ENDOTHELIN-2; and ENDOTHELIN-3. All three peptides contain 21 amino acids, but vary in amino acid composition. The three peptides produce vasoconstrictor and pressor responses in various parts of the body. However, the quantitative profiles of the pharmacological activities are considerably different among the three isopeptides.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.
Arteries which arise from the abdominal aorta and distribute to most of the intestines.
A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.
The outer zone of the KIDNEY, beneath the capsule, consisting of KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; and KIDNEY TUBULES, PROXIMAL.
A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
A drive stemming from a physiological need for WATER.
A flavoprotein enzyme that catalyzes the univalent reduction of OXYGEN using NADPH as an electron donor to create SUPEROXIDE ANION. The enzyme is dependent on a variety of CYTOCHROMES. Defects in the production of superoxide ions by enzymes such as NADPH oxidase result in GRANULOMATOUS DISEASE, CHRONIC.
Sodium excretion by URINATION.
A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
Drugs used to cause dilation of the blood vessels.
The geometric and structural changes that the HEART VENTRICLES undergo, usually following MYOCARDIAL INFARCTION. It comprises expansion of the infarct and dilatation of the healthy ventricle segments. While most prevalent in the left ventricle, it can also occur in the right ventricle.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
Antidiuretic hormones released by the NEUROHYPOPHYSIS of all vertebrates (structure varies with species) to regulate water balance and OSMOLARITY. In general, vasopressin is a nonapeptide consisting of a six-amino-acid ring with a cysteine 1 to cysteine 6 disulfide bridge or an octapeptide containing a CYSTINE. All mammals have arginine vasopressin except the pig with a lysine at position 8. Vasopressin, a vasoconstrictor, acts on the KIDNEY COLLECTING DUCTS to increase water reabsorption, increase blood volume and blood pressure.
The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.
The vessels carrying blood away from the heart.
A structure, situated close to the intraventricular foramen, which induces DRINKING BEHAVIOR after stimulation with ANGIOTENSIN II.
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
The renal tubule portion that extends from the BOWMAN CAPSULE in the KIDNEY CORTEX into the KIDNEY MEDULLA. The proximal tubule consists of a convoluted proximal segment in the cortex, and a distal straight segment descending into the medulla where it forms the U-shaped LOOP OF HENLE.
An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.
Sodium chloride used in foods.
A ubiquitous sodium salt that is commonly used to season food.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
A complex of cells consisting of juxtaglomerular cells, extraglomerular mesangium lacis cells, the macula densa of the distal convoluted tubule, and granular epithelial peripolar cells. Juxtaglomerular cells are modified SMOOTH MUSCLE CELLS found in the walls of afferent glomerular arterioles and sometimes the efferent arterioles. Extraglomerular mesangium lacis cells are located in the angle between the afferent and efferent glomerular arterioles. Granular epithelial peripolar cells are located at the angle of reflection of the parietal to visceral angle of the renal corpuscle.
A subtype of BRADYKININ RECEPTOR that is induced in response to INFLAMMATION. It may play a role in chronic inflammation and has a high specificity for KININS lacking the C-terminal ARGININE such as des-Arg(10)-kallidin and des-Arg(9)-bradykinin. The receptor is coupled to G-PROTEIN, GQ-G11 ALPHA FAMILY and G-PROTEIN, GI-GO ALPHA FAMILY signaling proteins.
A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, Oxidative Stress, 1991, pxv-xvi).
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
Cell surface proteins that bind ENDOTHELINS with high affinity and trigger intracellular changes which influence the behavior of cells.
Any of the tubular vessels conveying the blood (arteries, arterioles, capillaries, venules, and veins).
Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed)
An NADPH-dependent enzyme that catalyzes the conversion of L-ARGININE and OXYGEN to produce CITRULLINE and NITRIC OXIDE.
A subclass of EXOPEPTIDASES that act on the free N terminus end of a polypeptide liberating a single amino acid residue. EC 3.4.11.
A ZINC-dependent membrane-bound aminopeptidase that catalyzes the N-terminal peptide cleavage of GLUTAMATE (and to a lesser extent ASPARTATE). The enzyme appears to play a role in the catabolic pathway of the RENIN-ANGIOTENSIN SYSTEM.
A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes.
A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE.
The smallest divisions of the arteries located between the muscular arteries and the capillaries.
Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed)
Period of contraction of the HEART, especially of the HEART VENTRICLES.
The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance.
A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Treatment process involving the injection of fluid into an organ or tissue.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
The rate dynamics in chemical or physical systems.
The action of a drug in promoting or enhancing the effectiveness of another drug.
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
A phosphodiesterase inhibitor which inhibits platelet aggregation. Formerly used as an antineoplastic.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation.
An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
An increase in the excretion of URINE. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)
The flow of BLOOD through or around an organ or region of the body.
A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
A branch of the abdominal aorta which supplies the kidneys, adrenal glands and ureters.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Highly reactive compounds produced when oxygen is reduced by a single electron. In biological systems, they may be generated during the normal catalytic function of a number of enzymes and during the oxidation of hemoglobin to METHEMOGLOBIN. In living organisms, SUPEROXIDE DISMUTASE protects the cell from the deleterious effects of superoxides.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Injections into the cerebral ventricles.
Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of signal transduction and gene expression, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS.
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine.
Receptors in the vascular system, particularly the aorta and carotid sinus, which are sensitive to stretch of the vessel walls.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Narrowing or occlusion of the RENAL ARTERY or arteries. It is due usually to ATHEROSCLEROSIS; FIBROMUSCULAR DYSPLASIA; THROMBOSIS; EMBOLISM, or external pressure. The reduced renal perfusion can lead to renovascular hypertension (HYPERTENSION, RENOVASCULAR).
Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
A condition of abnormally low AMNIOTIC FLUID volume. Principal causes include malformations of fetal URINARY TRACT; FETAL GROWTH RETARDATION; GESTATIONAL HYPERTENSION; nicotine poisoning; and PROLONGED PREGNANCY.

Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. (1/4593)

Hypercholesterolemia and hypertension are frequently associated with elevated sympathetic activity. Both are independent cardiovascular risk factors and both affect endothelium-mediated vasodilation. To identify the effects of cholesterol-lowering and antihypertensive treatments on vascular reactivity and vasodilative capacity, we studied 30 hypercholesterolemic hypertensive subjects. They received placebo for 4 weeks, either enalapril or simvastatin for 14 weeks, and, finally, both medications for an additional 14 weeks. Postischemic forearm blood flow (MFBF) and minimal vascular resistance (mFVR) were used as indices of vasodilative capacity and structural vascular damage, respectively. Total (resting-stress-recovery phases) cardiovascular (blood pressure [BP] and heart rate [HR]) and regional hemodynamic (FBF and FVR) reactivity to stressful stimuli were calculated as area-under-the-curve (auc) (valuextime). Compared with baseline levels, simvastatin reduced total (TOT-C) and LDL cholesterol (LDL-C) (1.27 mmol/L, P<0.001 and 1.33 mmol/L, P<0.001, respectively). Enalapril also reduced TOT-C and LDL-C (0.6 mmol/L, P<0.001 and 0.58 mmol/L, P<0.05, respectively). MFBF was increased substantially by both treatments (P<0.001). Enalapril had a greater effect (-1.7 arbitrary units (AU), P<0.001) than simvastatin (-0.6 AU, P<0.05) on mFVR. During stress, FBF increased more with enalapril (4.4 FBFxminutes, P<0.001) than with simvastatin (1.8 FBFxminutes, P<0.01). Conversely, FVR stress response was reduced more with enalapril (9.1 FVRxminutes, P<0.001) than with simvastatin (2.9 FVRxminutes, P<0.01). During combination treatment, a significant (0.001>P<0.05) additive effect on hypercholesterolemia, structural vascular damage, BP, and FVR was shown. The findings suggest that angiotensin-converting enzyme (ACE) inhibition induces a larger reduction than HMG-CoA reductase blockade in vascular reactivity and structural damage in hypercholesterolemic hypertensive subjects.  (+info)

Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. (2/4593)

Impaired cardiac sympathetic activity can be evaluated by 123I-metaiodobenzylguanidine (MIBG) imaging. METHODS: We studied the significance of MIBG imaging for 24 patients (age 58+/-12 y) with dilated cardiomyopathy (DCM). We compared 12 patients (group A) treated with metoprolol (dose from 30-60 mg/d) with 12 patients treated with angiotensin-converting enzyme (ACE) inhibitors. Patients were studied before treatment, after 5 mo of treatment (only in group A) and after 1 y of treatment. Cardiac MIBG uptake was assessed as the heart-to-mediastinum activity ratio (H/M) and total defect score (TDS) from anterior planar and SPECT MIBG images, which were acquired in 4 h after tracer injection. New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) calculated by echocardiography were also assessed. RESULTS: TDS decreased in both groups (in group A, from 30+/-7 through 23+/-9 to 18+/-10; P < 0.01, in group B, from 30+/-6 to 24+/-8; P < 0.01) and H/M was increased in both groups (in group A, from 1.87+/-0.31 through 2.03+/-0.28 to 2.14+/-0.29; P < 0.01, in group B, from 1.82+/-0.28 to 1.94+/-0.26; P < 0.05). But TDS and H/M were more improved in group A than in group B (P < 0.05). LVEF was significantly increased in only group A (from 38+/-6 through 43+/-8 to 49%+/-9%; P < 0.01). NYHA improved in both groups (in group A, from mean 2.5 through 2.1 to 1.8; P < 0.01, in group B, from mean 2.6 to 2.1; P < 0.05) but was more improved in group A than in group B (P < 0.05). CONCLUSION: Cardiac function, symptom and cardiac sympathetic activity evaluated by MIBG images improved after the beta-blocker therapy more than with the treatment that used ACE inhibitors.  (+info)

Bradykinin promotes ischemic norepinephrine release in guinea pig and human hearts. (3/4593)

We previously reported that bradykinin (BK; 1-1000 nM) facilitates norepinephrine (NE) release from cardiac sympathetic nerves. Because BK production increases in myocardial ischemia, endogenous BK could foster NE release and associated arrhythmias. We tested this hypothesis in guinea pig and human myocardial ischemia models. BK administration (100 nM) markedly enhanced exocytotic and carrier-mediated NE overflow from guinea pig hearts subjected to 10- and 20-min ischemia/reperfusion, respectively. Ventricular fibrillation invariably occurred after 20-min global ischemia; BK prolonged its duration 3-fold. The BK B2 receptor antagonist HOE140 (30 nM) blocked the effects of BK, whereas the B1 receptor antagonist des-Arg9-Leu8-BK (1 microM; i.e., 2.5 x pA2) did not. When serine proteinase inhibitors (500 KIU/ml aprotinin and 100 microg/ml soybean trypsin inhibitor) were used to prevent the formation of endogenous BK, NE overflow and reperfusion arrhythmias were diminished. In contrast, when kininase I and II inhibitors (DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid and enalaprilat, each 1 microM) were used to prevent the degradation of endogenous BK, NE overflow and reperfusion arrhythmias were enhanced. B2 receptor blockade abolished these effects but was ineffective if kininases were not inhibited. B2 receptor stimulation, by either exogenous or endogenous BK, also markedly enhanced carrier-mediated NE release in the human myocardial ischemia model; conversely, inhibition of BK biosynthesis diminished ischemic NE release. Because atherosclerotic heart disease impairs endothelial BK production, in myocardial ischemia BK could accumulate at sympathetic nerve endings, thus augmenting exocytotic and carrier-mediated NE release and favoring coronary vasoconstriction and arrhythmias.  (+info)

Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. (4/4593)

BACKGROUND: The renin-angiotensin system is thought to be involved in the progression of glomerulonephritis (GN) into end-stage renal failure (ESRF) because of the observed renoprotective effects of angiotensin-converting enzyme inhibitors (ACEIs). However, ACEIs have pharmacological effects other than ACE inhibition that may help lower blood pressure and preserve glomerular structure. We previously reported a new animal model of progressive glomerulosclerosis induced by a single intravenous injection of an anti-Thy-1 monoclonal antibody, MoAb 1-22-3, in uninephrectomized rats. Using this new model of progressive GN, we examined the hypothesis that ACEIs prevent the progression to ESRF by modulating the effects of angiotensin II (Ang II) on the production of transforming growth factor-beta (TGF-beta) and extracellular matrix components. METHODS: We studied the effect of an ACEI (cilazapril) and an Ang II type 1 receptor antagonist (candesartan) on the clinical features and morphological lesions in the rat model previously reported. After 10 weeks of treatment with equihypotensive doses of cilazapril, cilazapril plus Hoe 140 (a bradykinin receptor B2 antagonist), candesartan, and hydralazine, we examined systolic blood pressure, urinary protein excretion, creatinine clearance, the glomerulosclerosis index, and the tubulointerstitial lesion index. We performed a semiquantitative evaluation of glomerular immunostaining for TGF-beta and collagen types I and III by immunofluorescence study and of these cortical mRNA levels by Northern blot analysis. RESULTS: Untreated rats developed massive proteinuria, renal dysfunction, and severe glomerular and tubulointerstitial injury, whereas uninephrectomized control rats did not. There was a significant increase in the levels of glomerular protein and cortical mRNA for TGF-beta and collagen types I and III in untreated rats. Cilazapril and candesartan prevented massive proteinuria, increased creatinine clearance, and ameliorated glomerular and tubulointerstitial injury. These drugs also reduced levels of glomerular protein and cortical mRNA for TGF-beta and collagen types I and III. Hoe 140 failed to blunt the renoprotective effect of cilazapril. Hydralazine did not exhibit a renoprotective effect. CONCLUSION: These results indicate that ACEIs prevent the progression to ESRF by modulating the effects of Ang II via Ang II type 1 receptor on the production of TGF-beta and collagen types I and III, as well as on intrarenal hemodynamics, but not by either increasing bradykinin activity or reducing blood pressure in this rat model of mesangial proliferative GN.  (+info)

Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. (5/4593)

BACKGROUND: In patients with insulin-dependent diabetes mellitus (IDDM) and overt nephropathy glomerular barrier size-selectivity progressively deteriorates with time and is effectively improved by angiotensin converting enzyme (ACE) inhibition. Whether similar glomerular functional changes develop in proteinuric patients with non-insulin-dependent diabetes mellitus (NIDDM), and whether antihypertensive agents can favorably affect glomerular filtration of macromolecules in these patients, has not been documented yet. METHODS: We investigated renal hemodynamics and fractional clearance of neutral dextrans of graded sizes, in nine proteinuric patients with NIDDM and renal biopsy findings of typical diabetic glomerulopathy. Six healthy volunteers served as controls. We also investigated the effects of an ACE inhibitor and of a calcium channel blocker, both given in doses targeted to achieve a comparable level of systemic blood pressure control, on glomerular hemodynamics and sieving function. Theoretical analysis of glomerular macromolecule transport was adopted to evaluate intrinsic glomerular membrane permeability properties. RESULTS: Fractional clearance of large macromolecules (42 to 66 A in radius) was significantly higher in diabetic patients than in controls, and the distribution of membrane pore radii was calculated to be shifted towards larger pore sizes in diabetics (mean radius increased from 55 to 60 A). Despite effective blood pressure control, neither antihypertensive affected glomerular hemodynamics to any significant extent. Fractional clearance of dextrans, as well as of albumin and IgG, and total urinary proteins were not modified by either treatments. CONCLUSIONS: These data indicate that patients with NIDDM and overt nephropathy develop abnormalities in size-selective function of the glomerular barrier and, at variance to IDDM, such changes were not ameliorated either by ACE inhibition or calcium channel blockade.  (+info)

Racial differences in the outcome of left ventricular dysfunction. (6/4593)

BACKGROUND: Population-based studies have found that black patients with congestive heart failure have a higher mortality rate than whites with the same condition. This finding has been attributed to differences in the severity, causes, and management of heart failure, the prevalence of coexisting conditions, and socioeconomic factors. Although these factors probably account for some of the higher mortality due to congestive heart failure among blacks, we hypothesized that racial differences in the natural history of left ventricular dysfunction might also have a role. METHODS: Using data from the Studies of Left Ventricular Dysfunction (SOLVD) prevention and treatment trials, in which all patients received standardized therapy and follow-up, we conducted a retrospective analysis of the outcomes of asymptomatic and symptomatic left ventricular systolic dysfunction among black and white participants. The mean (+/-SD) follow-up was 34.2+/-14.0 months in the prevention trial and 32.3+/-14.8 months in the treatment trial among the black and white participants. RESULTS: The overall mortality rates in the prevention trial were 8.1 per 100 person-years for blacks and 5.1 per 100 person years for whites. In the treatment trial, the rates were 16.7 per 100 person-years and 13.4 per 100 person-years, respectively. After adjustment for age, coexisting conditions, severity and causes of heart failure, and use of medications, blacks had a higher risk of death from all causes in both the SOLVD prevention trial (relative risk, 1.36; 95 percent confidence interval, 1.06 to 1.74; P=0.02) and the treatment trial (relative risk, 1.25; 95 percent confidence interval, 1.04 to 1.50; P=0.02). In both trials blacks were also at higher risk for death due to pump failure and for the combined end point of death from any cause or hospitalization for heart failure, our two predefined indicators of the progression of left ventricular systolic dysfunction. CONCLUSIONS: Blacks with mild-to-moderate left ventricular systolic dysfunction appear to be at higher risk for progression of heart failure and death from any cause than similarly treated whites. These results suggest that there may be racial differences in the outcome of asymptomatic and symptomatic left ventricular systolic dysfunction.  (+info)

Reduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists. (7/4593)

1. Subcutaneous injection of sodium deoxycholic acid into the anterior of the back of male ddY mice elicited dose-dependent scratching of the injected site with the forepaws and hindpaws. 2. Up to 100 microg of sodium deoxycholic acid induced no significant increase in vascular permeability at the injection site as assessed by a dye leakage method. 3. Bradykinin (BK) B2 receptor antagonists, FR173657 and Hoe140, significantly decreased the frequency of scratching induced by sodium deoxycholic acid. 4. Treatment with aprotinin to inhibit tissue kallikrein reduced the scratching behaviour induced by sodium deoxycholic acid, whereas treatment with soybean trypsin inhibitor to inhibit plasma kallikrein did not. 5. Although injection of kininase II inhibitor, lisinopril together with sodium deoxycholic acid did not alter the scratching behaviour, phosphoramidon, a neutral endopeptidase inhibitor, significantly increased the frequency of scratching. 6. Homogenates of the skin excised from the backs of mice were subjected to gel-filtration column chromatography followed by an assay of kinin release by trypsin from each fraction separated. Less kinin release from the fractions containing kininogen of low molecular weight was observed in the skin injected with sodium deoxycholic acid than in normal skin. 7. The frequency of scratching after the injection of sodium deoxycholic acid in plasma kininogen-deficient Brown Norway Katholiek rats was significantly lower than that in normal rats of the same strain, Brown Norway Kitasato rats. 8. These results indicate that BK released from low-molecular-weight kininogen by tissue kallikrein, but not from high-molecular-weight kininogen by plasma kallikrein, may be involved in the scratching behaviour induced by the injection of sodium deoxycholic acid in the rodent.  (+info)

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. (8/4593)

BACKGROUND: Incomplete suppression of the renin-angiotensin system during long-term ACE inhibition may contribute to symptomatic deterioration in patients with severe congestive heart failure (CHF). Combined angiotensin II type I (AT1) receptor blockade and ACE inhibition more completely suppresses the activated renin-angiotensin system than either intervention alone in sodium-depleted normal individuals. Whether AT1 receptor blockade with losartan improves exercise capacity in patients with severe CHF already treated with ACE inhibitors is unknown. METHODS AND RESULTS: Thirty-three patients with severe CHF despite treatment with maximally recommended or tolerated doses of ACE inhibitors were randomized 1:1 to receive 50 mg/d losartan or placebo for 6 months in addition to standard therapy in a multicenter, double-blind trial. Peak aerobic capacity (V(O2)) during symptom-limited treadmill exercise and NYHA functional class were determined at baseline and after 3 and 6 months of double-blind therapy. Peak V(O2) at baseline and after 3 and 6 months were 13.5+/-0.6, 15.1+/-1.0, and 15.7+/-1.1 mL. kg-1. min-1, respectively, in patients receiving losartan and 14.1+/-0.6, 14.3+/-0.9, and 13.6+/-1.1 mL. kg-1. min-1, respectively, in patients receiving placebo (P<0.02 for treatment group-by-time interaction). Functional class improved by at least one NYHA class in 9 of 16 patients receiving losartan and 1 of 17 patients receiving placebo. CONCLUSIONS: Losartan enhances peak exercise capacity and alleviates symptoms in patients with CHF who are severely symptomatic despite treatment with maximally recommended or tolerated doses of ACE inhibitors.  (+info)

There are two types of hypertension:

1. Primary Hypertension: This type of hypertension has no identifiable cause and is also known as essential hypertension. It accounts for about 90% of all cases of hypertension.
2. Secondary Hypertension: This type of hypertension is caused by an underlying medical condition or medication. It accounts for about 10% of all cases of hypertension.

Some common causes of secondary hypertension include:

* Kidney disease
* Adrenal gland disorders
* Hormonal imbalances
* Certain medications
* Sleep apnea
* Cocaine use

There are also several risk factors for hypertension, including:

* Age (the risk increases with age)
* Family history of hypertension
* Obesity
* Lack of exercise
* High sodium intake
* Low potassium intake
* Stress

Hypertension is often asymptomatic, and it can cause damage to the blood vessels and organs over time. Some potential complications of hypertension include:

* Heart disease (e.g., heart attacks, heart failure)
* Stroke
* Kidney disease (e.g., chronic kidney disease, end-stage renal disease)
* Vision loss (e.g., retinopathy)
* Peripheral artery disease

Hypertension is typically diagnosed through blood pressure readings taken over a period of time. Treatment for hypertension may include lifestyle changes (e.g., diet, exercise, stress management), medications, or a combination of both. The goal of treatment is to reduce the risk of complications and improve quality of life.

There are two main types of heart failure:

1. Left-sided heart failure: This occurs when the left ventricle, which is the main pumping chamber of the heart, becomes weakened and is unable to pump blood effectively. This can lead to congestion in the lungs and other organs.
2. Right-sided heart failure: This occurs when the right ventricle, which pumps blood to the lungs, becomes weakened and is unable to pump blood effectively. This can lead to congestion in the body's tissues and organs.

Symptoms of heart failure may include:

* Shortness of breath
* Fatigue
* Swelling in the legs, ankles, and feet
* Swelling in the abdomen
* Weight gain
* Coughing up pink, frothy fluid
* Rapid or irregular heartbeat
* Dizziness or lightheadedness

Treatment for heart failure typically involves a combination of medications and lifestyle changes. Medications may include diuretics to remove excess fluid from the body, ACE inhibitors or beta blockers to reduce blood pressure and improve blood flow, and aldosterone antagonists to reduce the amount of fluid in the body. Lifestyle changes may include a healthy diet, regular exercise, and stress reduction techniques. In severe cases, heart failure may require hospitalization or implantation of a device such as an implantable cardioverter-defibrillator (ICD) or a left ventricular assist device (LVAD).

It is important to note that heart failure is a chronic condition, and it requires ongoing management and monitoring to prevent complications and improve quality of life. With proper treatment and lifestyle changes, many people with heart failure are able to manage their symptoms and lead active lives.

A type of hypertension that is caused by a problem with the kidneys. It can be acute or chronic and may be associated with other conditions such as glomerulonephritis, pyelonephritis, or polycystic kidney disease. Symptoms include proteinuria, hematuria, and elevated blood pressure. Treatment options include diuretics, ACE inhibitors, and angiotensin II receptor blockers.

Note: Renal hypertension is also known as renal artery hypertension.

Proteinuria is usually diagnosed by a urine protein-to-creatinine ratio (P/C ratio) or a 24-hour urine protein collection. The amount and duration of proteinuria can help distinguish between different underlying causes and predict prognosis.

Proteinuria can have significant clinical implications, as it is associated with increased risk of cardiovascular disease, kidney damage, and malnutrition. Treatment of the underlying cause can help reduce or eliminate proteinuria.

Acute angioedema is usually triggered by an allergic reaction or exposure to certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), blood pressure medications, or antibiotics. It can also be caused by infections, insect bites, and other environmental triggers.

Chronic angioedema, on the other hand, is a more persistent form of the condition that can last for weeks, months, or even years. It is often associated with conditions such as hereditary angioedema (HAE), which is caused by a genetic defect that affects the production of a protein called C1 esterase inhibitor.

The symptoms of angioedema can vary depending on the location and severity of the swelling, but they typically include:

* Swelling in the face, hands, feet, or other parts of the body
* Redness and warmth of the affected area
* Pain or discomfort
* Difficulty breathing or swallowing (in severe cases)

There is no cure for angioedema, but there are several treatments available to help manage the symptoms. These may include:

* Antihistamines or corticosteroids to reduce inflammation and relieve itching
* Ice packs or cool compresses to reduce swelling
* Compression stockings or bandages to prevent fluid buildup
* Pain relief medications, such as ibuprofen or acetaminophen, to manage discomfort

In severe cases of angioedema, hospitalization may be necessary to provide more intensive treatment and monitoring. In some cases, injectable medications such as epinephrine or corticosteroids may be administered to help reduce swelling and prevent complications.

Overall, angioedema is a serious condition that requires prompt medical attention to manage symptoms and prevent complications. If you suspect you or someone else may have angioedema, it is important to seek medical help right away.

Symptoms of renovascular hypertension may include:

* High blood pressure that is resistant to treatment
* Flank pain or back pain
* Hematuria (blood in the urine)
* Proteinuria (excess protein in the urine)
* Decreased kidney function

Diagnosis of renovascular hypertension typically involves imaging tests such as angiography, CT or MRI angiography, or ultrasound to evaluate the renal arteries and identify any blockages or narrowing. Other tests such as arenography, captopril test, or adrenomedullin testing may also be used to support the diagnosis.

Treatment of renovascular hypertension typically involves medications to lower blood pressure, such as beta blockers, ACE inhibitors, or calcium channel blockers. In some cases, surgery may be necessary to restore blood flow to the kidneys. For example, atherosclerosis can be treated with angioplasty or bypass surgery.

It is important to note that renovascular hypertension is a relatively rare cause of hypertension and only accounts for about 5-10% of all cases of hypertension. However, it is an important differential diagnosis for hypertension that is resistant to treatment or has a sudden onset.

Medical Term: Cardiomegaly

Definition: An abnormal enlargement of the heart.

Symptoms: Difficulty breathing, shortness of breath, fatigue, swelling of legs and feet, chest pain, and palpitations.

Causes: Hypertension, cardiac valve disease, myocardial infarction (heart attack), congenital heart defects, and other conditions that affect the heart muscle or cardiovascular system.

Diagnosis: Physical examination, electrocardiogram (ECG), chest x-ray, echocardiography, and other diagnostic tests as necessary.

Treatment: Medications such as diuretics, vasodilators, and beta blockers, lifestyle changes such as exercise and diet modifications, surgery or other interventions in severe cases.

Note: Cardiomegaly is a serious medical condition that requires prompt diagnosis and treatment to prevent complications such as heart failure and death. If you suspect you or someone else may have cardiomegaly, seek medical attention immediately.

There are several types of diabetic nephropathy, including:

1. Mesangial proliferative glomerulonephritis: This is the most common type of diabetic nephropathy and is characterized by an overgrowth of cells in the mesangium, a part of the glomerulus (the blood-filtering unit of the kidney).
2. Segmental sclerosis: This type of diabetic nephropathy involves the hardening of some parts of the glomeruli, leading to decreased kidney function.
3. Fibrotic glomerulopathy: This is a rare form of diabetic nephropathy that is characterized by the accumulation of fibrotic tissue in the glomeruli.
4. Membranous nephropathy: This type of diabetic nephropathy involves the deposition of immune complexes (antigen-antibody complexes) in the glomeruli, leading to inflammation and damage to the kidneys.
5. Minimal change disease: This is a rare form of diabetic nephropathy that is characterized by minimal changes in the glomeruli, but with significant loss of kidney function.

The symptoms of diabetic nephropathy can be non-specific and may include proteinuria (excess protein in the urine), hematuria (blood in the urine), and decreased kidney function. Diagnosis is typically made through a combination of physical examination, medical history, laboratory tests, and imaging studies such as ultrasound or CT scans.

Treatment for diabetic nephropathy typically involves managing blood sugar levels through lifestyle changes (such as diet and exercise) and medication, as well as controlling high blood pressure and other underlying conditions. In severe cases, dialysis or kidney transplantation may be necessary. Early detection and management of diabetic nephropathy can help slow the progression of the disease and improve outcomes for patients with this condition.

Causes of Hyperkalemia:

1. Kidney dysfunction: When the kidneys are not able to excrete excess potassium, it can build up in the bloodstream and lead to hyperkalemia.
2. Medications: Certain drugs, such as ACE inhibitors, potassium-sparing diuretics, and NSAIDs, can increase potassium levels by blocking the excretion of potassium in the urine.
3. Diabetic ketoacidosis: High levels of potassium can occur in people with uncontrolled diabetes who have diabetic ketoacidosis.
4. Acute kidney injury: This condition can cause a rapid increase in potassium levels as the kidneys are unable to remove excess potassium from the blood.
5. Heart disease: Potassium levels can rise in people with heart failure or other cardiac conditions, leading to hyperkalemia.

Symptoms of Hyperkalemia:

1. Muscle weakness and fatigue
2. Abnormal heart rhythms (arrhythmias)
3. Palpitations
4. Constipation
5. Nausea and vomiting
6. Abdominal cramps
7. Fatigue
8. Confusion
9. Headaches
10. Weakness in the legs and feet

Treatment of Hyperkalemia:

The treatment of hyperkalemia depends on the underlying cause and the severity of the condition. Some of the common methods for lowering potassium levels include:

1. Diuretics: These medications help remove excess fluid and electrolytes, including potassium, from the body.
2. Calcium gluconate: This medication can help stabilize cardiac function and reduce the risk of arrhythmias.
3. Insulin and glucose: Giving insulin and glucose to someone with diabetic ketoacidosis can help lower potassium levels by increasing glucose uptake in the cells.
4. Hemodialysis: This is a process that uses a machine to filter waste products, including excess potassium, from the blood.
5. Potassium-binding resins: These medications can bind to potassium ions in the gut and prevent their absorption into the bloodstream.
6. Sodium polystyrene sulfonate (Kayexalate): This medication can help lower potassium levels by binding to excess potassium in the gut and causing it to be eliminated in the stool.
7. Activated charcoal: This medication can help bind to potassium ions in the gut and prevent their absorption into the bloodstream.

In severe cases of hyperkalemia, hospitalization may be necessary to monitor and treat the condition. In some instances, dialysis may be required to remove excess potassium from the blood. It is important to note that the treatment for hyperkalemia should only be done under the guidance of a healthcare professional, as some medications or procedures can worsen the condition if not properly managed.

Types of Kidney Diseases:

1. Acute Kidney Injury (AKI): A sudden and reversible loss of kidney function that can be caused by a variety of factors, such as injury, infection, or medication.
2. Chronic Kidney Disease (CKD): A gradual and irreversible loss of kidney function that can lead to end-stage renal disease (ESRD).
3. End-Stage Renal Disease (ESRD): A severe and irreversible form of CKD that requires dialysis or a kidney transplant.
4. Glomerulonephritis: An inflammation of the glomeruli, the tiny blood vessels in the kidneys that filter waste products.
5. Interstitial Nephritis: An inflammation of the tissue between the tubules and blood vessels in the kidneys.
6. Kidney Stone Disease: A condition where small, hard mineral deposits form in the kidneys and can cause pain, bleeding, and other complications.
7. Pyelonephritis: An infection of the kidneys that can cause inflammation, damage to the tissues, and scarring.
8. Renal Cell Carcinoma: A type of cancer that originates in the cells of the kidney.
9. Hemolytic Uremic Syndrome (HUS): A condition where the immune system attacks the platelets and red blood cells, leading to anemia, low platelet count, and damage to the kidneys.

Symptoms of Kidney Diseases:

1. Blood in urine or hematuria
2. Proteinuria (excess protein in urine)
3. Reduced kidney function or renal insufficiency
4. Swelling in the legs, ankles, and feet (edema)
5. Fatigue and weakness
6. Nausea and vomiting
7. Abdominal pain
8. Frequent urination or polyuria
9. Increased thirst and drinking (polydipsia)
10. Weight loss

Diagnosis of Kidney Diseases:

1. Physical examination
2. Medical history
3. Urinalysis (test of urine)
4. Blood tests (e.g., creatinine, urea, electrolytes)
5. Imaging studies (e.g., X-rays, CT scans, ultrasound)
6. Kidney biopsy
7. Other specialized tests (e.g., 24-hour urinary protein collection, kidney function tests)

Treatment of Kidney Diseases:

1. Medications (e.g., diuretics, blood pressure medication, antibiotics)
2. Diet and lifestyle changes (e.g., low salt intake, increased water intake, physical activity)
3. Dialysis (filtering waste products from the blood when the kidneys are not functioning properly)
4. Kidney transplantation ( replacing a diseased kidney with a healthy one)
5. Other specialized treatments (e.g., plasmapheresis, hemodialysis)

Prevention of Kidney Diseases:

1. Maintaining a healthy diet and lifestyle
2. Monitoring blood pressure and blood sugar levels
3. Avoiding harmful substances (e.g., tobacco, excessive alcohol consumption)
4. Managing underlying medical conditions (e.g., diabetes, high blood pressure)
5. Getting regular check-ups and screenings

Early detection and treatment of kidney diseases can help prevent or slow the progression of the disease, reducing the risk of complications and improving quality of life. It is important to be aware of the signs and symptoms of kidney diseases and seek medical attention if they are present.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

Fibrosis can occur in response to a variety of stimuli, including inflammation, infection, injury, or chronic stress. It is a natural healing process that helps to restore tissue function and structure after damage or trauma. However, excessive fibrosis can lead to the loss of tissue function and organ dysfunction.

There are many different types of fibrosis, including:

* Cardiac fibrosis: the accumulation of scar tissue in the heart muscle or walls, leading to decreased heart function and potentially life-threatening complications.
* Pulmonary fibrosis: the accumulation of scar tissue in the lungs, leading to decreased lung function and difficulty breathing.
* Hepatic fibrosis: the accumulation of scar tissue in the liver, leading to decreased liver function and potentially life-threatening complications.
* Neurofibromatosis: a genetic disorder characterized by the growth of benign tumors (neurofibromas) made up of fibrous connective tissue.
* Desmoid tumors: rare, slow-growing tumors that are made up of fibrous connective tissue and can occur in various parts of the body.

Fibrosis can be diagnosed through a variety of methods, including:

* Biopsy: the removal of a small sample of tissue for examination under a microscope.
* Imaging tests: such as X-rays, CT scans, or MRI scans to visualize the accumulation of scar tissue.
* Blood tests: to assess liver function or detect specific proteins or enzymes that are elevated in response to fibrosis.

There is currently no cure for fibrosis, but various treatments can help manage the symptoms and slow the progression of the condition. These may include:

* Medications: such as corticosteroids, immunosuppressants, or chemotherapy to reduce inflammation and slow down the growth of scar tissue.
* Lifestyle modifications: such as quitting smoking, exercising regularly, and maintaining a healthy diet to improve overall health and reduce the progression of fibrosis.
* Surgery: in some cases, surgical removal of the affected tissue or organ may be necessary.

It is important to note that fibrosis can progress over time, leading to further scarring and potentially life-threatening complications. Regular monitoring and follow-up with a healthcare professional are crucial to managing the condition and detecting any changes or progression early on.

Albuminuria is often associated with conditions such as diabetes, high blood pressure, and kidney disease, as these conditions can damage the kidneys and cause albumin to leak into the urine. It is also a common finding in people with chronic kidney disease (CKD), as the damaged kidneys are unable to filter out the excess protein.

If left untreated, albuminuria can lead to complications such as kidney failure, cardiovascular disease, and an increased risk of death. Treatment options for albuminuria include medications to lower blood pressure and control blood sugar levels, as well as dietary changes and lifestyle modifications. In severe cases, dialysis or kidney transplantation may be necessary.

In summary, albuminuria is the presence of albumin in the urine, which can be an indicator of kidney damage or disease. It is often associated with conditions such as diabetes and high blood pressure, and can lead to complications if left untreated.

There are several types of hypertrophy, including:

1. Muscle hypertrophy: The enlargement of muscle fibers due to increased protein synthesis and cell growth, often seen in individuals who engage in resistance training exercises.
2. Cardiac hypertrophy: The enlargement of the heart due to an increase in cardiac workload, often seen in individuals with high blood pressure or other cardiovascular conditions.
3. Adipose tissue hypertrophy: The excessive growth of fat cells, often seen in individuals who are obese or have insulin resistance.
4. Neurological hypertrophy: The enlargement of neural structures such as brain or spinal cord due to an increase in the number of neurons or glial cells, often seen in individuals with neurodegenerative diseases such as Alzheimer's or Parkinson's.
5. Hepatic hypertrophy: The enlargement of the liver due to an increase in the number of liver cells, often seen in individuals with liver disease or cirrhosis.
6. Renal hypertrophy: The enlargement of the kidneys due to an increase in blood flow and filtration, often seen in individuals with kidney disease or hypertension.
7. Ovarian hypertrophy: The enlargement of the ovaries due to an increase in the number of follicles or hormonal imbalances, often seen in individuals with polycystic ovary syndrome (PCOS).

Hypertrophy can be diagnosed through various medical tests such as imaging studies (e.g., CT scans, MRI), biopsies, and blood tests. Treatment options for hypertrophy depend on the underlying cause and may include medications, lifestyle changes, and surgery.

In conclusion, hypertrophy is a growth or enlargement of cells, tissues, or organs in response to an excessive stimulus. It can occur in various parts of the body, including the brain, liver, kidneys, heart, muscles, and ovaries. Understanding the underlying causes and diagnosis of hypertrophy is crucial for effective treatment and management of related health conditions.

LVH can lead to a number of complications, including:

1. Heart failure: The enlarged left ventricle can become less efficient at pumping blood throughout the body, leading to heart failure.
2. Arrhythmias: The abnormal electrical activity in the heart can lead to irregular heart rhythms.
3. Sudden cardiac death: In some cases, LVH can increase the risk of sudden cardiac death.
4. Atrial fibrillation: The enlarged left atrium can lead to atrial fibrillation, a common type of arrhythmia.
5. Mitral regurgitation: The enlargement of the left ventricle can cause the mitral valve to become incompetent, leading to mitral regurgitation.
6. Heart valve problems: The enlarged left ventricle can lead to heart valve problems, such as mitral regurgitation or aortic stenosis.
7. Coronary artery disease: LVH can increase the risk of coronary artery disease, which can lead to a heart attack.
8. Pulmonary hypertension: The enlarged left ventricle can lead to pulmonary hypertension, which can further strain the heart and increase the risk of complications.

Evaluation of LVH typically involves a physical examination, medical history, electrocardiogram (ECG), echocardiography, and other diagnostic tests such as stress test or cardiac MRI. Treatment options for LVH depend on the underlying cause and may include medications, lifestyle changes, and in some cases, surgery or other interventions.

A condition in which the kidneys gradually lose their function over time, leading to the accumulation of waste products in the body. Also known as chronic kidney disease (CKD).

Prevalence:

Chronic kidney failure affects approximately 20 million people worldwide and is a major public health concern. In the United States, it is estimated that 1 in 5 adults has CKD, with African Americans being disproportionately affected.

Causes:

The causes of chronic kidney failure are numerous and include:

1. Diabetes: High blood sugar levels can damage the kidneys over time.
2. Hypertension: Uncontrolled high blood pressure can cause damage to the blood vessels in the kidneys.
3. Glomerulonephritis: An inflammation of the glomeruli, the tiny blood vessels in the kidneys that filter waste and excess fluids from the blood.
4. Interstitial nephritis: Inflammation of the tissue between the kidney tubules.
5. Pyelonephritis: Infection of the kidneys, usually caused by bacteria or viruses.
6. Polycystic kidney disease: A genetic disorder that causes cysts to grow on the kidneys.
7. Obesity: Excess weight can increase blood pressure and strain on the kidneys.
8. Family history: A family history of kidney disease increases the risk of developing chronic kidney failure.

Symptoms:

Early stages of chronic kidney failure may not cause any symptoms, but as the disease progresses, symptoms can include:

1. Fatigue: Feeling tired or weak.
2. Swelling: In the legs, ankles, and feet.
3. Nausea and vomiting: Due to the buildup of waste products in the body.
4. Poor appetite: Loss of interest in food.
5. Difficulty concentrating: Cognitive impairment due to the buildup of waste products in the brain.
6. Shortness of breath: Due to fluid buildup in the lungs.
7. Pain: In the back, flank, or abdomen.
8. Urination changes: Decreased urine production, dark-colored urine, or blood in the urine.
9. Heart problems: Chronic kidney failure can increase the risk of heart disease and heart attack.

Diagnosis:

Chronic kidney failure is typically diagnosed based on a combination of physical examination findings, medical history, laboratory tests, and imaging studies. Laboratory tests may include:

1. Blood urea nitrogen (BUN) and creatinine: Waste products in the blood that increase with decreased kidney function.
2. Electrolyte levels: Imbalances in electrolytes such as sodium, potassium, and phosphorus can indicate kidney dysfunction.
3. Kidney function tests: Measurement of glomerular filtration rate (GFR) to determine the level of kidney function.
4. Urinalysis: Examination of urine for protein, blood, or white blood cells.

Imaging studies may include:

1. Ultrasound: To assess the size and shape of the kidneys, detect any blockages, and identify any other abnormalities.
2. Computed tomography (CT) scan: To provide detailed images of the kidneys and detect any obstructions or abscesses.
3. Magnetic resonance imaging (MRI): To evaluate the kidneys and detect any damage or scarring.

Treatment:

Treatment for chronic kidney failure depends on the underlying cause and the severity of the disease. The goals of treatment are to slow progression of the disease, manage symptoms, and improve quality of life. Treatment may include:

1. Medications: To control high blood pressure, lower cholesterol levels, reduce proteinuria, and manage anemia.
2. Diet: A healthy diet that limits protein intake, controls salt and water intake, and emphasizes low-fat dairy products, fruits, and vegetables.
3. Fluid management: Monitoring and control of fluid intake to prevent fluid buildup in the body.
4. Dialysis: A machine that filters waste products from the blood when the kidneys are no longer able to do so.
5. Transplantation: A kidney transplant may be considered for some patients with advanced chronic kidney failure.

Complications:

Chronic kidney failure can lead to several complications, including:

1. Heart disease: High blood pressure and anemia can increase the risk of heart disease.
2. Anemia: A decrease in red blood cells can cause fatigue, weakness, and shortness of breath.
3. Bone disease: A disorder that can lead to bone pain, weakness, and an increased risk of fractures.
4. Electrolyte imbalance: Imbalances of electrolytes such as potassium, phosphorus, and sodium can cause muscle weakness, heart arrhythmias, and other complications.
5. Infections: A decrease in immune function can increase the risk of infections.
6. Nutritional deficiencies: Poor appetite, nausea, and vomiting can lead to malnutrition and nutrient deficiencies.
7. Cardiovascular disease: High blood pressure, anemia, and other complications can increase the risk of cardiovascular disease.
8. Pain: Chronic kidney failure can cause pain, particularly in the back, flank, and abdomen.
9. Sleep disorders: Insomnia, sleep apnea, and restless leg syndrome are common complications.
10. Depression and anxiety: The emotional burden of chronic kidney failure can lead to depression and anxiety.

There are different types of myocardial infarctions, including:

1. ST-segment elevation myocardial infarction (STEMI): This is the most severe type of heart attack, where a large area of the heart muscle is damaged. It is characterized by a specific pattern on an electrocardiogram (ECG) called the ST segment.
2. Non-ST-segment elevation myocardial infarction (NSTEMI): This type of heart attack is less severe than STEMI, and the damage to the heart muscle may not be as extensive. It is characterized by a smaller area of damage or a different pattern on an ECG.
3. Incomplete myocardial infarction: This type of heart attack is when there is some damage to the heart muscle but not a complete blockage of blood flow.
4. Collateral circulation myocardial infarction: This type of heart attack occurs when there are existing collateral vessels that bypass the blocked coronary artery, which reduces the amount of damage to the heart muscle.

Symptoms of a myocardial infarction can include chest pain or discomfort, shortness of breath, lightheadedness, and fatigue. These symptoms may be accompanied by anxiety, fear, and a sense of impending doom. In some cases, there may be no noticeable symptoms at all.

Diagnosis of myocardial infarction is typically made based on a combination of physical examination findings, medical history, and diagnostic tests such as an electrocardiogram (ECG), cardiac enzyme tests, and imaging studies like echocardiography or cardiac magnetic resonance imaging.

Treatment of myocardial infarction usually involves medications to relieve pain, reduce the amount of work the heart has to do, and prevent further damage to the heart muscle. These may include aspirin, beta blockers, ACE inhibitors or angiotensin receptor blockers, and statins. In some cases, a procedure such as angioplasty or coronary artery bypass surgery may be necessary to restore blood flow to the affected area.

Prevention of myocardial infarction involves managing risk factors such as high blood pressure, high cholesterol, smoking, diabetes, and obesity. This can include lifestyle changes such as a healthy diet, regular exercise, and stress reduction, as well as medications to control these conditions. Early detection and treatment of heart disease can help prevent myocardial infarction from occurring in the first place.

Measurement:

Cardiac output is typically measured using invasive or non-invasive methods. Invasive methods involve inserting a catheter into the heart to directly measure cardiac output. Non-invasive methods include echocardiography, MRI, and CT scans. These tests can provide an estimate of cardiac output based on the volume of blood being pumped out of the heart and the rate at which it is being pumped.

Causes:

There are several factors that can contribute to low cardiac output. These include:

1. Heart failure: This occurs when the heart is unable to pump enough blood to meet the body's needs, leading to fatigue and shortness of breath.
2. Anemia: A low red blood cell count can reduce the amount of oxygen being delivered to the body's tissues, leading to fatigue and weakness.
3. Medication side effects: Certain medications, such as beta blockers, can slow down the heart rate and reduce cardiac output.
4. Sepsis: A severe infection can lead to inflammation throughout the body, which can affect the heart's ability to pump blood effectively.
5. Myocardial infarction (heart attack): This occurs when the heart muscle is damaged due to a lack of oxygen, leading to reduced cardiac output.

Symptoms:

Low cardiac output can cause a range of symptoms, including:

1. Fatigue and weakness
2. Dizziness and lightheadedness
3. Shortness of breath
4. Pale skin
5. Decreased urine output
6. Confusion and disorientation

Treatment:

The treatment of low cardiac output depends on the underlying cause. Treatment may include:

1. Medications to increase heart rate and contractility
2. Diuretics to reduce fluid buildup in the body
3. Oxygen therapy to increase oxygenation of tissues
4. Mechanical support devices, such as intra-aortic balloon pumps or ventricular assist devices
5. Surgery to repair or replace damaged heart tissue
6. Lifestyle changes, such as a healthy diet and regular exercise, to improve cardiovascular health.

Prevention:

Preventing low cardiac output involves managing any underlying medical conditions, taking medications as directed, and making lifestyle changes to improve cardiovascular health. This may include:

1. Monitoring and controlling blood pressure
2. Managing diabetes and other chronic conditions
3. Avoiding substances that can damage the heart, such as tobacco and excessive alcohol
4. Exercising regularly
5. Eating a healthy diet that is low in saturated fats and cholesterol
6. Maintaining a healthy weight.

During ventricular remodeling, the heart muscle becomes thicker and less flexible, leading to a decrease in the heart's ability to fill with blood and pump it out to the body. This can lead to shortness of breath, fatigue, and swelling in the legs and feet.

Ventricular remodeling is a natural response to injury, but it can also be exacerbated by factors such as high blood pressure, diabetes, and obesity. Treatment for ventricular remodeling typically involves medications and lifestyle changes, such as exercise and a healthy diet, to help manage symptoms and slow the progression of the condition. In some cases, surgery or other procedures may be necessary to repair or replace damaged heart tissue.

The process of ventricular remodeling is complex and involves multiple cellular and molecular mechanisms. It is thought to be driven by a variety of factors, including changes in gene expression, inflammation, and the activity of various signaling pathways.

Overall, ventricular remodeling is an important condition that can have significant consequences for patients with heart disease. Understanding its causes and mechanisms is crucial for developing effective treatments and improving outcomes for those affected by this condition.

Body weight is an important health indicator, as it can affect an individual's risk for certain medical conditions, such as obesity, diabetes, and cardiovascular disease. Maintaining a healthy body weight is essential for overall health and well-being, and there are many ways to do so, including a balanced diet, regular exercise, and other lifestyle changes.

There are several ways to measure body weight, including:

1. Scale: This is the most common method of measuring body weight, and it involves standing on a scale that displays the individual's weight in kg or lb.
2. Body fat calipers: These are used to measure body fat percentage by pinching the skin at specific points on the body.
3. Skinfold measurements: This method involves measuring the thickness of the skin folds at specific points on the body to estimate body fat percentage.
4. Bioelectrical impedance analysis (BIA): This is a non-invasive method that uses electrical impulses to measure body fat percentage.
5. Dual-energy X-ray absorptiometry (DXA): This is a more accurate method of measuring body composition, including bone density and body fat percentage.

It's important to note that body weight can fluctuate throughout the day due to factors such as water retention, so it's best to measure body weight at the same time each day for the most accurate results. Additionally, it's important to use a reliable scale or measuring tool to ensure accurate measurements.

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the World Health Organization (WHO). In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

In this article, we will explore the definition and impact of chronic diseases, as well as strategies for managing and living with them. We will also discuss the importance of early detection and prevention, as well as the role of healthcare providers in addressing the needs of individuals with chronic diseases.

What is a Chronic Disease?

A chronic disease is a condition that lasts for an extended period of time, often affecting daily life and activities. Unlike acute diseases, which have a specific beginning and end, chronic diseases are long-term and persistent. Examples of chronic diseases include:

1. Diabetes
2. Heart disease
3. Arthritis
4. Asthma
5. Cancer
6. Chronic obstructive pulmonary disease (COPD)
7. Chronic kidney disease (CKD)
8. Hypertension
9. Osteoporosis
10. Stroke

Impact of Chronic Diseases

The burden of chronic diseases is significant, with over 70% of deaths worldwide attributed to them, according to the WHO. In addition to the physical and emotional toll they take on individuals and their families, chronic diseases also pose a significant economic burden, accounting for a large proportion of healthcare expenditure.

Chronic diseases can also have a significant impact on an individual's quality of life, limiting their ability to participate in activities they enjoy and affecting their relationships with family and friends. Moreover, the financial burden of chronic diseases can lead to poverty and reduce economic productivity, thus having a broader societal impact.

Addressing Chronic Diseases

Given the significant burden of chronic diseases, it is essential that we address them effectively. This requires a multi-faceted approach that includes:

1. Lifestyle modifications: Encouraging healthy behaviors such as regular physical activity, a balanced diet, and smoking cessation can help prevent and manage chronic diseases.
2. Early detection and diagnosis: Identifying risk factors and detecting diseases early can help prevent or delay their progression.
3. Medication management: Effective medication management is crucial for controlling symptoms and slowing disease progression.
4. Multi-disciplinary care: Collaboration between healthcare providers, patients, and families is essential for managing chronic diseases.
5. Health promotion and disease prevention: Educating individuals about the risks of chronic diseases and promoting healthy behaviors can help prevent their onset.
6. Addressing social determinants of health: Social determinants such as poverty, education, and employment can have a significant impact on health outcomes. Addressing these factors is essential for reducing health disparities and improving overall health.
7. Investing in healthcare infrastructure: Investing in healthcare infrastructure, technology, and research is necessary to improve disease detection, diagnosis, and treatment.
8. Encouraging policy change: Policy changes can help create supportive environments for healthy behaviors and reduce the burden of chronic diseases.
9. Increasing public awareness: Raising public awareness about the risks and consequences of chronic diseases can help individuals make informed decisions about their health.
10. Providing support for caregivers: Chronic diseases can have a significant impact on family members and caregivers, so providing them with support is essential for improving overall health outcomes.

Conclusion

Chronic diseases are a major public health burden that affect millions of people worldwide. Addressing these diseases requires a multi-faceted approach that includes lifestyle changes, addressing social determinants of health, investing in healthcare infrastructure, encouraging policy change, increasing public awareness, and providing support for caregivers. By taking a comprehensive approach to chronic disease prevention and management, we can improve the health and well-being of individuals and communities worldwide.

There are several causes of hypotension, including:

1. Dehydration: Loss of fluids and electrolytes can cause a drop in blood pressure.
2. Blood loss: Losing too much blood can lead to hypotension.
3. Medications: Certain medications, such as diuretics and beta-blockers, can lower blood pressure.
4. Heart conditions: Heart failure, cardiac tamponade, and arrhythmias can all cause hypotension.
5. Endocrine disorders: Hypothyroidism (underactive thyroid) and adrenal insufficiency can cause low blood pressure.
6. Vasodilation: A condition where the blood vessels are dilated, leading to low blood pressure.
7. Sepsis: Severe infection can cause hypotension.

Symptoms of hypotension can include:

1. Dizziness and lightheadedness
2. Fainting or passing out
3. Weakness and fatigue
4. Confusion and disorientation
5. Pale, cool, or clammy skin
6. Fast or weak pulse
7. Shortness of breath
8. Nausea and vomiting

If you suspect that you or someone else is experiencing hypotension, it is important to seek medical attention immediately. Treatment will depend on the underlying cause of the condition, but may include fluids, electrolytes, and medication to raise blood pressure. In severe cases, hospitalization may be necessary.

There are several potential causes of LVD, including:

1. Coronary artery disease: The buildup of plaque in the coronary arteries can lead to a heart attack, which can damage the left ventricle and impair its ability to function properly.
2. Heart failure: When the heart is unable to pump enough blood to meet the body's needs, it can lead to LVD.
3. Cardiomyopathy: This is a condition where the heart muscle becomes weakened or enlarged, leading to impaired function of the left ventricle.
4. Heart valve disease: Problems with the heart valves can disrupt the normal flow of blood and cause LVD.
5. Hypertension: High blood pressure can cause damage to the heart muscle and lead to LVD.
6. Genetic factors: Some people may be born with genetic mutations that predispose them to developing LVD.
7. Viral infections: Certain viral infections, such as myocarditis, can inflame and damage the heart muscle, leading to LVD.
8. Alcohol or drug abuse: Substance abuse can damage the heart muscle and lead to LVD.
9. Nutritional deficiencies: A diet lacking essential nutrients can lead to damage to the heart muscle and increase the risk of LVD.

Diagnosis of LVD typically involves a physical exam, medical history, and results of diagnostic tests such as electrocardiograms (ECGs), echocardiograms, and stress tests. Treatment options for LVD depend on the underlying cause, but may include medications to improve cardiac function, lifestyle changes, and in severe cases, surgery or other procedures.

Preventing LVD involves taking steps to maintain a healthy heart and reducing risk factors such as high blood pressure, smoking, and obesity. This can be achieved through a balanced diet, regular exercise, stress management, and avoiding substance abuse. Early detection and treatment of underlying conditions that increase the risk of LVD can also help prevent the condition from developing.

The term cough is used to describe a wide range of symptoms that can be caused by various conditions affecting the respiratory system. Coughs can be classified as either dry or productive, depending on whether they produce mucus or not. Dry coughs are often described as hacking, barking, or non-productive, while productive coughs are those that bring up mucus or other substances from the lungs or airways.

Causes of Cough:

There are many potential causes of cough, including:

* Upper respiratory tract infections such as the common cold and influenza
* Lower respiratory tract infections such as bronchitis and pneumonia
* Allergies, including hay fever and allergic rhinitis
* Asthma and other chronic lung conditions
* Gastroesophageal reflux disease (GERD), which can cause coughing due to stomach acid flowing back up into the throat
* Environmental factors such as smoke, dust, and pollution
* Medications such as ACE inhibitors and beta blockers.

Symptoms of Cough:

In addition to the characteristic forceful expulsion of air from the lungs, coughs can be accompanied by a range of other symptoms that may include:

* Chest tightness or discomfort
* Shortness of breath or wheezing
* Fatigue and exhaustion
* Headache
* Sore throat or hoarseness
* Coughing up mucus or other substances.

Diagnosis and Treatment of Cough:

The diagnosis and treatment of cough will depend on the underlying cause. In some cases, a cough may be a symptom of a more serious condition that requires medical attention, such as pneumonia or asthma. In other cases, a cough may be caused by a minor infection or allergy that can be treated with over-the-counter medications and self-care measures.

Some common treatments for cough include:

* Cough suppressants such as dextromethorphan or pholcodine to relieve the urge to cough
* Expectorants such as guaifenesin to help loosen and clear mucus from the airways
* Antihistamines to reduce the severity of allergic reactions and help relieve a cough.
* Antibiotics if the cough is caused by a bacterial infection
* Inhalers and nebulizers to deliver medication directly to the lungs.

It is important to note that while cough can be a symptom of a serious condition, it is not always necessary to see a doctor for a cough. However, if you experience any of the following, you should seek medical attention:

* A persistent and severe cough that lasts for more than a few days or weeks
* A cough that worsens at night or with exertion
* Coughing up blood or mucus that is thick and yellow or greenish in color
* Shortness of breath or chest pain
* Fever, chills, or body aches that are severe or persistent.

It is also important to note that while over-the-counter medications can provide relief from symptoms, they may not address the underlying cause of the cough. If you have a persistent or severe cough, it is important to see a doctor to determine the cause and receive proper treatment.

1. Coronary artery disease: The narrowing or blockage of the coronary arteries, which supply blood to the heart.
2. Heart failure: A condition in which the heart is unable to pump enough blood to meet the body's needs.
3. Arrhythmias: Abnormal heart rhythms that can be too fast, too slow, or irregular.
4. Heart valve disease: Problems with the heart valves that control blood flow through the heart.
5. Heart muscle disease (cardiomyopathy): Disease of the heart muscle that can lead to heart failure.
6. Congenital heart disease: Defects in the heart's structure and function that are present at birth.
7. Peripheral artery disease: The narrowing or blockage of blood vessels that supply oxygen and nutrients to the arms, legs, and other organs.
8. Deep vein thrombosis (DVT): A blood clot that forms in a deep vein, usually in the leg.
9. Pulmonary embolism: A blockage in one of the arteries in the lungs, which can be caused by a blood clot or other debris.
10. Stroke: A condition in which there is a lack of oxygen to the brain due to a blockage or rupture of blood vessels.

Renal artery obstruction can be caused by a variety of factors, including:

1. Atherosclerosis (hardening of the arteries): This is the most common cause of renal artery obstruction and occurs when plaque builds up in the arteries, leading to narrowing or blockages.
2. Stenosis (narrowing of the arteries): This can be caused by inflammation or scarring of the arteries, which can lead to a decrease in blood flow to the kidneys.
3. Fibromuscular dysplasia: This is a rare condition that causes abnormal growth of muscle tissue in the renal arteries, leading to narrowing or blockages.
4. Embolism (blood clot): A blood clot can break loose and travel to the kidneys, causing a blockage in the renal artery.
5. Renal vein thrombosis: This is a blockage of the veins that drain blood from the kidneys, which can lead to decreased blood flow and oxygenation of the kidneys.

Symptoms of renal artery obstruction may include:

1. High blood pressure
2. Decreased kidney function
3. Swelling in the legs or feet
4. Pain in the flank or back
5. Fatigue
6. Nausea and vomiting
7. Weight loss

Diagnosis of renal artery obstruction is typically made through a combination of physical examination, medical history, and diagnostic tests such as:

1. Ultrasound: This can help identify any blockages or narrowing in the renal arteries.
2. Computed tomography (CT) scan: This can provide detailed images of the renal arteries and any blockages or narrowing.
3. Magnetic resonance angiogram (MRA): This is a non-invasive test that uses magnetic fields and radio waves to create detailed images of the renal arteries.
4. Angiography: This is a minimally invasive test that involves inserting a catheter into the renal artery to visualize any blockages or narrowing.

Treatment for renal artery obstruction depends on the underlying cause and severity of the condition. Some possible treatment options include:

1. Medications: Drugs such as blood thinners, blood pressure medication, and anticoagulants may be prescribed to manage symptoms and slow the progression of the disease.
2. Endovascular therapy: This is a minimally invasive procedure in which a catheter is inserted into the renal artery to open up any blockages or narrowing.
3. Surgery: In some cases, surgery may be necessary to remove any blockages or repair any damage to the renal arteries.
4. Dialysis: This is a procedure in which waste products are removed from the blood when the kidneys are no longer able to do so.
5. Kidney transplantation: In severe cases of renal artery obstruction, a kidney transplant may be necessary.

It is important to note that early detection and treatment of renal artery obstruction can help prevent complications and improve outcomes for patients.

Causes:

There are several possible causes of oligohydramnios, including:

1. Premature rupture of membranes (PROM): This is when the amniotic sac that surrounds the fetus bursts early, before 37 weeks of gestation.
2. Preterm labor: When a woman goes into labor before 37 weeks of gestation, the amount of amniotic fluid may decrease.
3. Uteroplacental blood flow abnormalities: These can occur when there are problems with the placenta or the uterus that affect the flow of blood and oxygen to the fetus.
4. Maternal diabetes: Diabetes in the mother can cause a decrease in amniotic fluid.
5. Infections: Certain infections, such as group B streptococcus, can cause a decrease in amniotic fluid.
6. Kidney or urinary tract problems in the mother: These can affect the amount of amniotic fluid produced.
7. Multiple gestations (twins, triplets): The amount of amniotic fluid may be lower in multiple pregnancies.
8. Abnormal fetal development: In some cases, a chromosomal abnormality or other fetal problem can cause a decrease in amniotic fluid.

Symptoms:

Women with oligohydramnios may experience few or no symptoms at all. However, some women may notice:

1. Decreased fetal movement: With less amniotic fluid, the fetus may not be able to move as much, making it feel less active or even still.
2. Abnormal fetal positioning: The fetus may not be able to move into a normal position for delivery, which can make the delivery more difficult.
3. Increased risk of umbilical cord compression: If the umbilical cord is compressed by the placenta or other tissues, it can cause a decrease in blood flow to the fetus, leading to distress and potentially even stillbirth.
4. Preterm labor: Women with oligohydramnios may be at increased risk of going into preterm labor.

Treatment and Management:

There is no specific treatment for oligohydramnios. However, the condition is often monitored closely during pregnancy to ensure that the fetus is healthy and growing properly. The following steps may be taken to manage oligohydramnios:

1. Close monitoring: Regular ultrasound examinations are used to check the amount of amniotic fluid and fetal growth.
2. Fetal movement monitoring: The fetus's movements may be monitored to ensure that it is still active and healthy.
3. Increased prenatal care: Women with oligohydramnios may require more frequent prenatal appointments to monitor the condition and ensure that the fetus is healthy.
4. Hydration: Drinking plenty of water and other fluids can help to increase the amount of amniotic fluid.
5. Bed rest: In some cases, women with oligohydramnios may be advised to rest in bed to reduce the risk of preterm labor.
6. Medications: In severe cases, medications such as corticosteroids may be prescribed to help mature the fetal lungs and increase the chances of survival if the baby is born prematurely.
7. Induction of labor: If the condition persists or the fetus is not growing properly, induction of labor may be considered.

In conclusion, oligohydramnios can be a serious complication during pregnancy that can increase the risk of stillbirth and other complications. However, with close monitoring and appropriate management, the outcomes for both mother and baby can be improved. It is essential to work closely with a healthcare provider to monitor the condition and make any necessary adjustments to ensure a healthy pregnancy.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Type 2 diabetes can be managed through a combination of diet, exercise, and medication. In some cases, lifestyle changes may be enough to control blood sugar levels, while in other cases, medication or insulin therapy may be necessary. Regular monitoring of blood sugar levels and follow-up with a healthcare provider are important for managing the condition and preventing complications.

Common symptoms of type 2 diabetes include:

* Increased thirst and urination
* Fatigue
* Blurred vision
* Cuts or bruises that are slow to heal
* Tingling or numbness in the hands and feet
* Recurring skin, gum, or bladder infections

If left untreated, type 2 diabetes can lead to a range of complications, including:

* Heart disease and stroke
* Kidney damage and failure
* Nerve damage and pain
* Eye damage and blindness
* Foot damage and amputation

The exact cause of type 2 diabetes is not known, but it is believed to be linked to a combination of genetic and lifestyle factors, such as:

* Obesity and excess body weight
* Lack of physical activity
* Poor diet and nutrition
* Age and family history
* Certain ethnicities (e.g., African American, Hispanic/Latino, Native American)
* History of gestational diabetes or delivering a baby over 9 lbs.

There is no cure for type 2 diabetes, but it can be managed and controlled through a combination of lifestyle changes and medication. With proper treatment and self-care, people with type 2 diabetes can lead long, healthy lives.

In addition to the high blood pressure, people with malignant hypertension may experience other signs and symptoms, such as:

* Seizures or coma
* Vision changes or loss of vision
* Numbness or weakness in the face, arm, or leg
* Confusion or disorientation
* Slurred speech
* Difficulty speaking or swallowing
* Severe headache
* Neck stiffness
* Fever
* Pain in the chest, abdomen, or flank

If left untreated, malignant hypertension can lead to a range of complications and organ damage, including:

* Heart attack or heart failure
* Stroke or cerebral hemorrhage
* Kidney failure or renal impairment
* Seizures or coma
* Vision loss or blindness
* Peripheral artery disease or limb gangrene

Treatment of malignant hypertension typically involves aggressive medication to lower blood pressure and manage symptoms, as well as careful monitoring in a hospital setting. In severe cases, surgery or other interventions may be necessary to treat underlying conditions or repair damaged organs. With prompt and appropriate treatment, the outlook for people with malignant hypertension can improve significantly, but delays in diagnosis and treatment can have serious consequences.

Previous articleWhat is the Meaning of Aphasia? Next article What is the Medical Definition of CVA?

There are two main types of Renal Insufficiency:

1. Acute Kidney Injury (AKI): This is a sudden and reversible decrease in kidney function, often caused by injury, sepsis, or medication toxicity. AKI can resolve with appropriate treatment and supportive care.
2. Chronic Renal Insufficiency (CRI): This is a long-standing and irreversible decline in kidney function, often caused by diabetes, high blood pressure, or chronic kidney disease. CRI can lead to ESRD if left untreated.

Signs and symptoms of Renal Insufficiency may include:

* Decreased urine output
* Swelling in the legs and ankles (edema)
* Fatigue
* Nausea and vomiting
* Shortness of breath (dyspnea)
* Pain in the back, flank, or abdomen

Diagnosis of Renal Insufficiency is typically made through a combination of physical examination, medical history, laboratory tests, and imaging studies. Laboratory tests may include urinalysis, blood urea nitrogen (BUN) and creatinine levels, and a 24-hour urine protein collection. Imaging studies, such as ultrasound or CT scans, may be used to evaluate the kidneys and rule out other possible causes of the patient's symptoms.

Treatment of Renal Insufficiency depends on the underlying cause and the severity of the condition. Treatment may include medications to control blood pressure, manage fluid balance, and reduce proteinuria (excess protein in the urine). In some cases, dialysis or a kidney transplant may be necessary.

Prevention of Renal Insufficiency includes managing underlying conditions such as diabetes and hypertension, avoiding nephrotoxic medications and substances, and maintaining a healthy diet and lifestyle. Early detection and treatment of acute kidney injury can also help prevent the development of chronic renal insufficiency.

In conclusion, Renal Insufficiency is a common condition that can have significant consequences if left untreated. It is important for healthcare providers to be aware of the causes, symptoms, and diagnosis of Renal Insufficiency, as well as the treatment and prevention strategies available. With appropriate management, many patients with Renal Insufficiency can recover and maintain their kidney function over time.

The term "segmental" refers to the fact that the scarring or hardening occurs in a specific segment of the glomerulus. Focal segmental glomerulosclerosis can be caused by a variety of factors, including diabetes, high blood pressure, and certain infections or injuries.

Symptoms of focal segmental glomerulosclerosis may include proteinuria (excess protein in the urine), hematuria (blood in the urine), and decreased kidney function. Treatment options vary depending on the underlying cause, but may include medications to control high blood pressure or diabetes, as well as immunosuppressive drugs in cases where the condition is caused by an autoimmune disorder. In severe cases, dialysis or kidney transplantation may be necessary.

GN IGA is one of the most common forms of idiopathic membranous nephropathy, which means it has no known cause. It can occur at any age but is more common in adults between the ages of 20 and 40. The disease often progresses slowly over several years, and some people may experience no symptoms at all.

The diagnosis of GN IGA is based on a combination of clinical findings, laboratory tests, and kidney biopsy. Laboratory tests may show abnormal levels of proteins in the urine, such as albumin, and a high level of IgA in the blood. A kidney biopsy is often necessary to confirm the diagnosis and to rule out other kidney diseases.

There is no cure for GN IGA, but treatment can help slow the progression of the disease. Treatment options may include medications to control high blood pressure, reduce proteinuria (excess protein in the urine), and suppress the immune system. In severe cases, dialysis or a kidney transplant may be necessary.

Preventive measures for GN IGA are not well established, but maintaining a healthy lifestyle, including a balanced diet, regular exercise, and avoiding exposure to toxins, may help reduce the risk of developing the disease. It is also important to manage any underlying medical conditions, such as high blood pressure or diabetes, which can increase the risk of kidney damage.

There are several possible causes of dilated cardiomyopathy, including:

1. Coronary artery disease: This is the most common cause of dilated cardiomyopathy, and it occurs when the coronary arteries become narrowed or blocked, leading to a decrease in blood flow to the heart muscle.
2. High blood pressure: Prolonged high blood pressure can cause the heart muscle to become weakened and enlarged.
3. Heart valve disease: Dysfunctional heart valves can lead to an increased workload on the heart, which can cause dilated cardiomyopathy.
4. Congenital heart defects: Some congenital heart defects can lead to an enlarged heart and dilated cardiomyopathy.
5. Alcohol abuse: Chronic alcohol abuse can damage the heart muscle and lead to dilated cardiomyopathy.
6. Viral infections: Some viral infections, such as myocarditis, can cause inflammation of the heart muscle and lead to dilated cardiomyopathy.
7. Genetic disorders: Certain genetic disorders, such as hypertrophic cardiomyopathy, can cause dilated cardiomyopathy.
8. Obesity: Obesity is a risk factor for developing dilated cardiomyopathy, particularly in younger people.
9. Diabetes: Diabetes can increase the risk of developing dilated cardiomyopathy, especially if left untreated or poorly controlled.
10. Age: Dilated cardiomyopathy is more common in older adults, with the majority of cases occurring in people over the age of 65.

It's important to note that many people with these risk factors will not develop dilated cardiomyopathy, and some people without any known risk factors can still develop the condition. If you suspect you or someone you know may have dilated cardiomyopathy, it's important to consult a healthcare professional for proper diagnosis and treatment.

The definition of AKI has evolved over time, and it is now defined as a syndrome characterized by an abrupt or rapid decrease in kidney function, with or without oliguria (decreased urine production), and with evidence of tubular injury. The RIFLE (Risk, Injury, Failure, Loss, and End-stage kidney disease) criteria are commonly used to diagnose and stage AKI based on serum creatinine levels, urine output, and other markers of kidney damage.

There are three stages of AKI, with stage 1 representing mild injury and stage 3 representing severe and potentially life-threatening injury. Treatment of AKI typically involves addressing the underlying cause, correcting fluid and electrolyte imbalances, and providing supportive care to maintain blood pressure and oxygenation. In some cases, dialysis may be necessary to remove waste products from the blood.

Early detection and treatment of AKI are crucial to prevent long-term damage to the kidneys and improve outcomes for patients.

Myocardial ischemia can be caused by a variety of factors, including coronary artery disease, high blood pressure, diabetes, and smoking. It can also be triggered by physical exertion or stress.

There are several types of myocardial ischemia, including:

1. Stable angina: This is the most common type of myocardial ischemia, and it is characterized by a predictable pattern of chest pain that occurs during physical activity or emotional stress.
2. Unstable angina: This is a more severe type of myocardial ischemia that can occur without any identifiable trigger, and can be accompanied by other symptoms such as shortness of breath or vomiting.
3. Acute coronary syndrome (ACS): This is a condition that includes both stable angina and unstable angina, and it is characterized by a sudden reduction in blood flow to the heart muscle.
4. Heart attack (myocardial infarction): This is a type of myocardial ischemia that occurs when the blood flow to the heart muscle is completely blocked, resulting in damage or death of the cardiac tissue.

Myocardial ischemia can be diagnosed through a variety of tests, including electrocardiograms (ECGs), stress tests, and imaging studies such as echocardiography or cardiac magnetic resonance imaging (MRI). Treatment options for myocardial ischemia include medications such as nitrates, beta blockers, and calcium channel blockers, as well as lifestyle changes such as quitting smoking, losing weight, and exercising regularly. In severe cases, surgical procedures such as coronary artery bypass grafting or angioplasty may be necessary.

Types of Experimental Diabetes Mellitus include:

1. Streptozotocin-induced diabetes: This type of EDM is caused by administration of streptozotocin, a chemical that damages the insulin-producing beta cells in the pancreas, leading to high blood sugar levels.
2. Alloxan-induced diabetes: This type of EDM is caused by administration of alloxan, a chemical that also damages the insulin-producing beta cells in the pancreas.
3. Pancreatectomy-induced diabetes: In this type of EDM, the pancreas is surgically removed or damaged, leading to loss of insulin production and high blood sugar levels.

Experimental Diabetes Mellitus has several applications in research, including:

1. Testing new drugs and therapies for diabetes treatment: EDM allows researchers to evaluate the effectiveness of new treatments on blood sugar control and other physiological processes.
2. Studying the pathophysiology of diabetes: By inducing EDM in animals, researchers can study the progression of diabetes and its effects on various organs and tissues.
3. Investigating the role of genetics in diabetes: Researchers can use EDM to study the effects of genetic mutations on diabetes development and progression.
4. Evaluating the efficacy of new diagnostic techniques: EDM allows researchers to test new methods for diagnosing diabetes and monitoring blood sugar levels.
5. Investigating the complications of diabetes: By inducing EDM in animals, researchers can study the development of complications such as retinopathy, nephropathy, and cardiovascular disease.

In conclusion, Experimental Diabetes Mellitus is a valuable tool for researchers studying diabetes and its complications. The technique allows for precise control over blood sugar levels and has numerous applications in testing new treatments, studying the pathophysiology of diabetes, investigating the role of genetics, evaluating new diagnostic techniques, and investigating complications.

There are several types of cardiomyopathies, each with distinct characteristics and symptoms. Some of the most common forms of cardiomyopathy include:

1. Hypertrophic cardiomyopathy (HCM): This is the most common form of cardiomyopathy and is characterized by an abnormal thickening of the heart muscle, particularly in the left ventricle. HCM can lead to obstruction of the left ventricular outflow tract and can increase the risk of sudden death.
2. Dilated cardiomyopathy: This type of cardiomyopathy is characterized by a decrease in the heart's ability to pump blood effectively, leading to enlargement of the heart and potentially life-threatening complications such as congestive heart failure.
3. Restrictive cardiomyopathy: This type of cardiomyopathy is characterized by stiffness of the heart muscle, which makes it difficult for the heart to fill with blood. This can lead to shortness of breath and fatigue.
4. Left ventricular non-compaction (LVNC): This is a rare type of cardiomyopathy that occurs when the left ventricle does not properly compact, leading to reduced cardiac function and potentially life-threatening complications.
5. Cardiac amyloidosis: This is a condition in which abnormal proteins accumulate in the heart tissue, leading to stiffness and impaired cardiac function.
6. Right ventricular cardiomyopathy (RVCM): This type of cardiomyopathy is characterized by impaired function of the right ventricle, which can lead to complications such as pulmonary hypertension and heart failure.
7. Endocardial fibroelastoma: This is a rare type of cardiomyopathy that occurs when abnormal tissue grows on the inner lining of the heart, leading to reduced cardiac function and potentially life-threatening complications.
8. Cardiac sarcoidosis: This is a condition in which inflammatory cells accumulate in the heart, leading to impaired cardiac function and potentially life-threatening complications.
9. Hypertrophic cardiomyopathy (HCM): This is a condition in which the heart muscle thickens, leading to reduced cardiac function and potentially life-threatening complications such as arrhythmias and sudden death.
10. Hypokinetic left ventricular cardiomyopathy: This type of cardiomyopathy is characterized by decreased contraction of the left ventricle, leading to reduced cardiac function and potentially life-threatening complications such as heart failure.

It's important to note that some of these types of cardiomyopathy are more common in certain populations, such as hypertrophic cardiomyopathy being more common in young athletes. Additionally, some types of cardiomyopathy may have overlapping symptoms or co-occurring conditions, so it's important to work with a healthcare provider for an accurate diagnosis and appropriate treatment.

The term "decerebrate" comes from the Latin word "cerebrum," which means brain. In this context, the term refers to a state where the brain is significantly damaged or absent, leading to a loss of consciousness and other cognitive functions.

Some common symptoms of the decerebrate state include:

* Loss of consciousness
* Flaccid paralysis (loss of muscle tone)
* Dilated pupils
* Lack of responsiveness to stimuli
* Poor or absent reflexes
* Inability to speak or communicate

The decerebrate state can be caused by a variety of factors, including:

* Severe head injury
* Stroke or cerebral vasculature disorders
* Brain tumors or cysts
* Infections such as meningitis or encephalitis
* Traumatic brain injury

Treatment for the decerebrate state is typically focused on addressing the underlying cause of the condition. This may involve medications to control seizures, antibiotics for infections, or surgery to relieve pressure on the brain. In some cases, the decerebrate state may be a permanent condition, and individuals may require long-term care and support.

The buildup of plaque in the coronary arteries is often caused by high levels of low-density lipoprotein (LDL) cholesterol, smoking, high blood pressure, diabetes, and a family history of heart disease. The plaque can also rupture, causing a blood clot to form, which can completely block the flow of blood to the heart muscle, leading to a heart attack.

CAD is the most common type of heart disease and is often asymptomatic until a serious event occurs. Risk factors for CAD include:

* Age (men over 45 and women over 55)
* Gender (men are at greater risk than women, but women are more likely to die from CAD)
* Family history of heart disease
* High blood pressure
* High cholesterol
* Diabetes
* Smoking
* Obesity
* Lack of exercise

Diagnosis of CAD typically involves a physical exam, medical history, and results of diagnostic tests such as:

* Electrocardiogram (ECG or EKG)
* Stress test
* Echocardiogram
* Coronary angiography

Treatment for CAD may include lifestyle changes such as a healthy diet, regular exercise, stress management, and quitting smoking. Medications such as beta blockers, ACE inhibitors, and statins may also be prescribed to manage symptoms and slow the progression of the disease. In severe cases, surgical intervention such as coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) may be necessary.

Prevention of CAD includes managing risk factors such as high blood pressure, high cholesterol, and diabetes, quitting smoking, maintaining a healthy weight, and getting regular exercise. Early detection and treatment of CAD can help to reduce the risk of complications and improve quality of life for those affected by the disease.

There are several types of diabetes mellitus, including:

1. Type 1 DM: This is an autoimmune condition in which the body's immune system attacks and destroys the cells in the pancreas that produce insulin, resulting in a complete deficiency of insulin production. It typically develops in childhood or adolescence, and patients with this condition require lifelong insulin therapy.
2. Type 2 DM: This is the most common form of diabetes, accounting for around 90% of all cases. It is caused by a combination of insulin resistance (where the body's cells do not respond properly to insulin) and impaired insulin secretion. It is often associated with obesity, physical inactivity, and a diet high in sugar and unhealthy fats.
3. Gestational DM: This type of diabetes develops during pregnancy, usually in the second or third trimester. Hormonal changes and insulin resistance can cause blood sugar levels to rise, putting both the mother and baby at risk.
4. LADA (Latent Autoimmune Diabetes in Adults): This is a form of type 1 DM that develops in adults, typically after the age of 30. It shares features with both type 1 and type 2 DM.
5. MODY (Maturity-Onset Diabetes of the Young): This is a rare form of diabetes caused by genetic mutations that affect insulin production. It typically develops in young adulthood and can be managed with lifestyle changes and/or medication.

The symptoms of diabetes mellitus can vary depending on the severity of the condition, but may include:

1. Increased thirst and urination
2. Fatigue
3. Blurred vision
4. Cuts or bruises that are slow to heal
5. Tingling or numbness in hands and feet
6. Recurring skin, gum, or bladder infections
7. Flu-like symptoms such as weakness, dizziness, and stomach pain
8. Dark, velvety skin patches (acanthosis nigricans)
9. Yellowish color of the skin and eyes (jaundice)
10. Delayed healing of cuts and wounds

If left untreated, diabetes mellitus can lead to a range of complications, including:

1. Heart disease and stroke
2. Kidney damage and failure
3. Nerve damage (neuropathy)
4. Eye damage (retinopathy)
5. Foot damage (neuropathic ulcers)
6. Cognitive impairment and dementia
7. Increased risk of infections and other diseases, such as pneumonia, gum disease, and urinary tract infections.

It is important to note that not all individuals with diabetes will experience these complications, and that proper management of the condition can greatly reduce the risk of developing these complications.

Synonyms: Bronchial Constriction, Airway Spasm, Reversible Airway Obstruction.

Antonyms: Bronchodilation, Relaxation of Bronchial Muscles.

Example Sentences:

1. The patient experienced bronchial spasms during the asthma attack and was treated with an inhaler.
2. The bronchial spasm caused by the allergic reaction was relieved by administering epinephrine.
3. The doctor prescribed corticosteroids to reduce inflammation and prevent future bronchial spasms.

1. Heart Disease: High blood sugar levels can damage the blood vessels and increase the risk of heart disease, which includes conditions like heart attacks, strokes, and peripheral artery disease.
2. Kidney Damage: Uncontrolled diabetes can damage the kidneys over time, leading to chronic kidney disease and potentially even kidney failure.
3. Nerve Damage: High blood sugar levels can damage the nerves in the body, causing numbness, tingling, and pain in the hands and feet. This is known as diabetic neuropathy.
4. Eye Problems: Diabetes can cause changes in the blood vessels of the eyes, leading to vision problems and even blindness. This is known as diabetic retinopathy.
5. Infections: People with diabetes are more prone to developing skin infections, urinary tract infections, and other types of infections due to their weakened immune system.
6. Amputations: Poor blood flow and nerve damage can lead to amputations of the feet or legs if left untreated.
7. Cognitive Decline: Diabetes has been linked to an increased risk of cognitive decline and dementia.
8. Sexual Dysfunction: Men with diabetes may experience erectile dysfunction, while women with diabetes may experience decreased sexual desire and vaginal dryness.
9. Gum Disease: People with diabetes are more prone to developing gum disease and other oral health problems due to their increased risk of infection.
10. Flu and Pneumonia: Diabetes can weaken the immune system, making it easier to catch the flu and pneumonia.

It is important for people with diabetes to manage their condition properly to prevent or delay these complications from occurring. This includes monitoring blood sugar levels regularly, taking medication as prescribed by a doctor, and following a healthy diet and exercise plan. Regular check-ups with a healthcare provider can also help identify any potential complications early on and prevent them from becoming more serious.

Coronary disease is often caused by a combination of genetic and lifestyle factors, such as high blood pressure, high cholesterol levels, smoking, obesity, and a lack of physical activity. It can also be triggered by other medical conditions, such as diabetes and kidney disease.

The symptoms of coronary disease can vary depending on the severity of the condition, but may include:

* Chest pain or discomfort (angina)
* Shortness of breath
* Fatigue
* Swelling of the legs and feet
* Pain in the arms and back

Coronary disease is typically diagnosed through a combination of physical examination, medical history, and diagnostic tests such as electrocardiograms (ECGs), stress tests, and cardiac imaging. Treatment for coronary disease may include lifestyle changes, medications to control symptoms, and surgical procedures such as angioplasty or bypass surgery to improve blood flow to the heart.

Preventative measures for coronary disease include:

* Maintaining a healthy diet and exercise routine
* Quitting smoking and limiting alcohol consumption
* Managing high blood pressure, high cholesterol levels, and other underlying medical conditions
* Reducing stress through relaxation techniques or therapy.

The symptoms of glomerulonephritis can vary depending on the underlying cause of the disease, but may include:

* Blood in the urine (hematuria)
* Proteinuria (excess protein in the urine)
* Reduced kidney function
* Swelling in the legs and ankles (edema)
* High blood pressure

Glomerulonephritis can be caused by a variety of factors, including:

* Infections such as staphylococcal or streptococcal infections
* Autoimmune disorders such as lupus or rheumatoid arthritis
* Allergic reactions to certain medications
* Genetic defects
* Certain diseases such as diabetes, high blood pressure, and sickle cell anemia

The diagnosis of glomerulonephritis typically involves a physical examination, medical history, and laboratory tests such as urinalysis, blood tests, and kidney biopsy.

Treatment for glomerulonephritis depends on the underlying cause of the disease and may include:

* Antibiotics to treat infections
* Medications to reduce inflammation and swelling
* Diuretics to reduce fluid buildup in the body
* Immunosuppressive medications to suppress the immune system in cases of autoimmune disorders
* Dialysis in severe cases

The prognosis for glomerulonephritis depends on the underlying cause of the disease and the severity of the inflammation. In some cases, the disease may progress to end-stage renal disease, which requires dialysis or a kidney transplant. With proper treatment, however, many people with glomerulonephritis can experience a good outcome and maintain their kidney function over time.

There are several key features of inflammation:

1. Increased blood flow: Blood vessels in the affected area dilate, allowing more blood to flow into the tissue and bringing with it immune cells, nutrients, and other signaling molecules.
2. Leukocyte migration: White blood cells, such as neutrophils and monocytes, migrate towards the site of inflammation in response to chemical signals.
3. Release of mediators: Inflammatory mediators, such as cytokines and chemokines, are released by immune cells and other cells in the affected tissue. These molecules help to coordinate the immune response and attract more immune cells to the site of inflammation.
4. Activation of immune cells: Immune cells, such as macrophages and T cells, become activated and start to phagocytose (engulf) pathogens or damaged tissue.
5. Increased heat production: Inflammation can cause an increase in metabolic activity in the affected tissue, leading to increased heat production.
6. Redness and swelling: Increased blood flow and leakiness of blood vessels can cause redness and swelling in the affected area.
7. Pain: Inflammation can cause pain through the activation of nociceptors (pain-sensing neurons) and the release of pro-inflammatory mediators.

Inflammation can be acute or chronic. Acute inflammation is a short-term response to injury or infection, which helps to resolve the issue quickly. Chronic inflammation is a long-term response that can cause ongoing damage and diseases such as arthritis, asthma, and cancer.

There are several types of inflammation, including:

1. Acute inflammation: A short-term response to injury or infection.
2. Chronic inflammation: A long-term response that can cause ongoing damage and diseases.
3. Autoimmune inflammation: An inappropriate immune response against the body's own tissues.
4. Allergic inflammation: An immune response to a harmless substance, such as pollen or dust mites.
5. Parasitic inflammation: An immune response to parasites, such as worms or fungi.
6. Bacterial inflammation: An immune response to bacteria.
7. Viral inflammation: An immune response to viruses.
8. Fungal inflammation: An immune response to fungi.

There are several ways to reduce inflammation, including:

1. Medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying anti-rheumatic drugs (DMARDs).
2. Lifestyle changes, such as a healthy diet, regular exercise, stress management, and getting enough sleep.
3. Alternative therapies, such as acupuncture, herbal supplements, and mind-body practices.
4. Addressing underlying conditions, such as hormonal imbalances, gut health issues, and chronic infections.
5. Using anti-inflammatory compounds found in certain foods, such as omega-3 fatty acids, turmeric, and ginger.

It's important to note that chronic inflammation can lead to a range of health problems, including:

1. Arthritis
2. Diabetes
3. Heart disease
4. Cancer
5. Alzheimer's disease
6. Parkinson's disease
7. Autoimmune disorders, such as lupus and rheumatoid arthritis.

Therefore, it's important to manage inflammation effectively to prevent these complications and improve overall health and well-being.

There are several risk factors for developing AF, including:

1. Age: The risk of developing AF increases with age, with the majority of cases occurring in people over the age of 65.
2. Hypertension (high blood pressure): High blood pressure can damage the heart and increase the risk of developing AF.
3. Heart disease: People with heart disease, such as coronary artery disease or heart failure, are at higher risk of developing AF.
4. Diabetes mellitus: Diabetes can increase the risk of developing AF.
5. Sleep apnea: Sleep apnea can increase the risk of developing AF.
6. Certain medications: Certain medications, such as thyroid medications and asthma medications, can increase the risk of developing AF.
7. Alcohol consumption: Excessive alcohol consumption has been linked to an increased risk of developing AF.
8. Smoking: Smoking is a risk factor for many cardiovascular conditions, including AF.
9. Obesity: Obesity is a risk factor for many cardiovascular conditions, including AF.

Symptoms of AF can include:

1. Palpitations (rapid or irregular heartbeat)
2. Shortness of breath
3. Fatigue
4. Dizziness or lightheadedness
5. Chest pain or discomfort

AF can be diagnosed with the help of several tests, including:

1. Electrocardiogram (ECG): This is a non-invasive test that measures the electrical activity of the heart.
2. Holter monitor: This is a portable device that records the heart's rhythm over a 24-hour period.
3. Event monitor: This is a portable device that records the heart's rhythm over a longer period of time, usually 1-2 weeks.
4. Echocardiogram: This is an imaging test that uses sound waves to create pictures of the heart.
5. Cardiac MRI: This is an imaging test that uses magnetic fields and radio waves to create detailed pictures of the heart.

Treatment for AF depends on the underlying cause and may include medications, such as:

1. Beta blockers: These medications slow the heart rate and reduce the force of the heart's contractions.
2. Antiarrhythmics: These medications help regulate the heart's rhythm.
3. Blood thinners: These medications prevent blood clots from forming and can help reduce the risk of stroke.
4. Calcium channel blockers: These medications slow the entry of calcium into the heart muscle cells, which can help slow the heart rate and reduce the force of the heart's contractions.

In some cases, catheter ablation may be recommended to destroy the abnormal electrical pathway causing AF. This is a minimally invasive procedure that involves inserting a catheter through a vein in the leg and guiding it to the heart using x-ray imaging. Once the catheter is in place, energy is applied to the abnormal electrical pathway to destroy it and restore a normal heart rhythm.

It's important to note that AF can increase the risk of stroke, so anticoagulation therapy may be recommended to reduce this risk. This can include medications such as warfarin or aspirin, or in some cases, implantable devices such as a left atrial appendage closure device.

In conclusion, atrial fibrillation is a common heart rhythm disorder that can increase the risk of stroke and heart failure. Treatment options depend on the underlying cause and may include medications, cardioversion, catheter ablation, or anticoagulation therapy. It's important to work closely with a healthcare provider to determine the best course of treatment for AF.

The disease begins with endothelial dysfunction, which allows lipid accumulation in the artery wall. Macrophages take up oxidized lipids and become foam cells, which die and release their contents, including inflammatory cytokines, leading to further inflammation and recruitment of more immune cells.

The atherosclerotic plaque can rupture or ulcerate, leading to the formation of a thrombus that can occlude the blood vessel, causing ischemia or infarction of downstream tissues. This can lead to various cardiovascular diseases such as myocardial infarction (heart attack), stroke, and peripheral artery disease.

Atherosclerosis is a multifactorial disease that is influenced by genetic and environmental factors such as smoking, hypertension, diabetes, high cholesterol levels, and obesity. It is diagnosed by imaging techniques such as angiography, ultrasound, or computed tomography (CT) scans.

Treatment options for atherosclerosis include lifestyle modifications such as smoking cessation, dietary changes, and exercise, as well as medications such as statins, beta blockers, and angiotensin-converting enzyme (ACE) inhibitors. In severe cases, surgical interventions such as bypass surgery or angioplasty may be necessary.

In conclusion, atherosclerosis is a complex and multifactorial disease that affects the arteries and can lead to various cardiovascular diseases. Early detection and treatment can help prevent or slow down its progression, reducing the risk of complications and improving patient outcomes.

There are several types of diabetic angiopathies, including:

1. Peripheral artery disease (PAD): This occurs when the blood vessels in the legs and arms become narrowed or blocked, leading to reduced blood flow and oxygen supply to the limbs.
2. Peripheral neuropathy: This is damage to the nerves in the hands and feet, which can cause pain, numbness, and weakness.
3. Retinopathy: This is damage to the blood vessels in the retina, which can lead to vision loss and blindness.
4. Nephropathy: This is damage to the kidneys, which can lead to kidney failure and the need for dialysis.
5. Cardiovascular disease: This includes heart attack, stroke, and other conditions that affect the heart and blood vessels.

The risk of developing diabetic angiopathies increases with the duration of diabetes and the level of blood sugar control. Other factors that can increase the risk include high blood pressure, high cholesterol, smoking, and a family history of diabetes-related complications.

Symptoms of diabetic angiopathies can vary depending on the specific type of complication and the location of the affected blood vessels or nerves. Common symptoms include:

* Pain or discomfort in the arms, legs, hands, or feet
* Numbness or tingling sensations in the hands and feet
* Weakness or fatigue in the limbs
* Difficulty healing wounds or cuts
* Vision changes or blindness
* Kidney problems or failure
* Heart attack or stroke

Diagnosis of diabetic angiopathies typically involves a combination of physical examination, medical history, and diagnostic tests such as ultrasound, MRI, or CT scans. Treatment options vary depending on the specific type of complication and may include:

* Medications to control blood sugar levels, high blood pressure, and high cholesterol
* Lifestyle changes such as a healthy diet and regular exercise
* Surgery to repair or bypass affected blood vessels or nerves
* Dialysis for kidney failure
* In some cases, amputation of the affected limb

Preventing diabetic angiopathies involves managing diabetes effectively through a combination of medication, lifestyle changes, and regular medical check-ups. Early detection and treatment can help prevent or delay the progression of complications.

The symptoms of chronic renal insufficiency can be subtle and may develop gradually over time. They may include fatigue, weakness, swelling in the legs and ankles, nausea, vomiting, and difficulty concentrating. As the disease progresses, patients may experience shortness of breath, heart failure, and peripheral artery disease.

Chronic renal insufficiency is diagnosed through blood tests that measure the level of waste products in the blood, such as creatinine and urea. Imaging studies, such as ultrasound and CT scans, may also be used to evaluate the kidneys and detect any damage or scarring.

Treatment for chronic renal insufficiency focuses on slowing the progression of the disease and managing its symptoms. This may include medications to control high blood pressure, diabetes, and anemia, as well as dietary changes and fluid restrictions. In severe cases, dialysis or kidney transplantation may be necessary.

Prevention of chronic renal insufficiency involves managing underlying conditions such as diabetes and hypertension, maintaining a healthy diet and exercise routine, and avoiding substances that can damage the kidneys, such as tobacco and excessive alcohol consumption. Early detection and treatment of kidney disease can help prevent the progression to chronic renal insufficiency.

There are many different types of heart diseases, including:

1. Coronary artery disease: The buildup of plaque in the coronary arteries, which supply blood to the heart muscle, leading to chest pain or a heart attack.
2. Heart failure: When the heart is unable to pump enough blood to meet the body's needs, leading to fatigue, shortness of breath, and swelling in the legs.
3. Arrhythmias: Abnormal heart rhythms, such as atrial fibrillation or ventricular tachycardia, which can cause palpitations, dizziness, and shortness of breath.
4. Heart valve disease: Problems with the heart valves, which can lead to blood leaking back into the chambers or not being pumped effectively.
5. Cardiomyopathy: Disease of the heart muscle, which can lead to weakened heart function and heart failure.
6. Heart murmurs: Abnormal sounds heard during a heartbeat, which can be caused by defects in the heart valves or abnormal blood flow.
7. Congenital heart disease: Heart defects present at birth, such as holes in the heart or abnormal blood vessels.
8. Myocardial infarction (heart attack): Damage to the heart muscle due to a lack of oxygen, often caused by a blockage in a coronary artery.
9. Cardiac tamponade: Fluid accumulation around the heart, which can cause compression of the heart and lead to cardiac arrest.
10. Endocarditis: Infection of the inner lining of the heart, which can cause fever, fatigue, and heart valve damage.

Heart diseases can be diagnosed through various tests such as electrocardiogram (ECG), echocardiogram, stress test, and blood tests. Treatment options depend on the specific condition and may include lifestyle changes, medication, surgery, or a combination of these.

Nephrosclerosis can be caused by a variety of factors, including:

1. Diabetes: High blood sugar levels over an extended period can damage the kidney tissues and lead to nephrosclerosis.
2. Hypertension: Uncontrolled high blood pressure can cause damage to the kidney blood vessels, leading to scarring and hardening of the tissues.
3. Glomerulonephritis: An inflammation of the glomeruli, the tiny blood vessels in the kidneys that filter waste and excess fluids from the blood, can lead to nephrosclerosis.
4. Obesity: Excess weight can increase the risk of developing diabetes and hypertension, both of which are leading causes of nephrosclerosis.
5. Family history: A family history of kidney disease increases the risk of developing nephrosclerosis.
6. Certain medications: Long-term use of certain medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) and certain antibiotics can damage the kidneys and lead to nephrosclerosis.
7. Infections: Certain infections, such as pyelonephritis, can spread to the kidneys and cause inflammation and scarring that leads to nephrosclerosis.
8. Kidney stones: Recurring kidney stones can cause chronic inflammation and damage to the kidney tissues, leading to nephrosclerosis.
9. Certain medical conditions: Certain medical conditions, such as systemic lupus erythematosus and vasculitis, can increase the risk of developing nephrosclerosis.

Symptoms of nephrosclerosis may include:

1. Proteinuria: Excess protein in the urine.
2. Hematuria: Blood in the urine.
3. Reduced kidney function: Decreased ability of the kidneys to filter waste and excess fluids from the blood.
4. High blood pressure: Hypertension is common in people with nephrosclerosis.
5. Swelling: Fluid retention in the legs, ankles, and feet.
6. Fatigue: Weakness and tiredness due to the buildup of waste products in the body.
7. Nausea and vomiting: Due to the buildup of waste products in the body.
8. Skin rash: Some people with nephrosclerosis may develop a skin rash.

Nephrosclerosis can be diagnosed through a combination of physical examination, medical history, urine and blood tests, and imaging studies such as ultrasound and CT scans. Treatment for nephrosclerosis depends on the underlying cause and may include medications to control high blood pressure, reduce proteinuria, and slow the progression of the disease. In severe cases, dialysis or kidney transplantation may be necessary.

It is essential to seek medical attention if you experience any symptoms of nephrosclerosis, as early diagnosis and treatment can help prevent complications and improve outcomes. A healthcare professional can perform a physical examination, take a medical history, and order diagnostic tests to determine the underlying cause of your symptoms. Based on the severity and underlying cause of your condition, a treatment plan will be developed that may include medications, lifestyle modifications, or dialysis. With proper treatment, many people with nephrosclerosis can manage their symptoms and improve their quality of life.

1. Ischemic stroke: This is the most common type of stroke, accounting for about 87% of all strokes. It occurs when a blood vessel in the brain becomes blocked, reducing blood flow to the brain.
2. Hemorrhagic stroke: This type of stroke occurs when a blood vessel in the brain ruptures, causing bleeding in the brain. High blood pressure, aneurysms, and blood vessel malformations can all cause hemorrhagic strokes.
3. Transient ischemic attack (TIA): Also known as a "mini-stroke," a TIA is a temporary interruption of blood flow to the brain that lasts for a short period of time, usually less than 24 hours. TIAs are often a warning sign for a future stroke and should be taken seriously.

Stroke can cause a wide range of symptoms depending on the location and severity of the damage to the brain. Some common symptoms include:

* Weakness or numbness in the face, arm, or leg
* Difficulty speaking or understanding speech
* Sudden vision loss or double vision
* Dizziness, loss of balance, or sudden falls
* Severe headache
* Confusion, disorientation, or difficulty with memory

Stroke is a leading cause of long-term disability and can have a significant impact on the quality of life for survivors. However, with prompt medical treatment and rehabilitation, many people are able to recover some or all of their lost functions and lead active lives.

The medical community has made significant progress in understanding stroke and developing effective treatments. Some of the most important advances include:

* Development of clot-busting drugs and mechanical thrombectomy devices to treat ischemic strokes
* Improved imaging techniques, such as CT and MRI scans, to diagnose stroke and determine its cause
* Advances in surgical techniques for hemorrhagic stroke
* Development of new medications to prevent blood clots and reduce the risk of stroke

Despite these advances, stroke remains a significant public health problem. According to the American Heart Association, stroke is the fifth leading cause of death in the United States and the leading cause of long-term disability. In 2017, there were over 795,000 strokes in the United States alone.

There are several risk factors for stroke that can be controlled or modified. These include:

* High blood pressure
* Diabetes mellitus
* High cholesterol levels
* Smoking
* Obesity
* Lack of physical activity
* Poor diet

In addition to these modifiable risk factors, there are also several non-modifiable risk factors for stroke, such as age (stroke risk increases with age), family history of stroke, and previous stroke or transient ischemic attack (TIA).

The medical community has made significant progress in understanding the causes and risk factors for stroke, as well as developing effective treatments and prevention strategies. However, more research is needed to improve outcomes for stroke survivors and reduce the overall burden of this disease.

The exact cause of endomyocardial fibrosis is not known, but it is believed to be related to inflammation and scarring within the heart. The condition is more common in men than women, and typically affects people between the ages of 20 and 50. Symptoms of endomyocardial fibrosis can include shortness of breath, fatigue, swelling in the legs and feet, and chest pain.

There is no cure for endomyocardial fibrosis, but treatment options may include medications to manage symptoms, surgery to repair or replace damaged heart tissue, and lifestyle changes such as a healthy diet and regular exercise. In severe cases, heart transplantation may be necessary. Early diagnosis and treatment can help slow the progression of the condition and improve quality of life for those affected.

Some common types of sclerosis include:

1. Multiple sclerosis (MS): This is an autoimmune disease that affects the central nervous system (CNS), causing inflammation and damage to the protective covering of nerve fibers, leading to communication problems between the brain and the rest of the body.
2. Systemic sclerosis (SSc): Also known as scleroderma, this is a chronic autoimmune disease that affects the skin and internal organs, causing hardening and tightening of the skin and scar tissue formation in the affected areas.
3. Progressive supranuclear palsy (PSP): This is a rare brain disorder that affects movement, balance, and eye movements, caused by degeneration of certain cells in the brainstem.
4. Primary lateral sclerosis (PLS): This is a rare neurodegenerative disorder that affects the motor neurons in the spinal cord, leading to weakness in the muscles of the legs, feet, and hands.
5. Tuberous sclerosis complex (TSC): This is a rare genetic disorder that causes non-cancerous tumors to grow in organs such as the brain, heart, kidneys, and lungs.

Symptoms of sclerosis vary depending on the type and location of the condition. Common symptoms include muscle weakness or stiffness, difficulty with movement and coordination, numbness or tingling sensations, and changes in sensation or perception. Treatment options for sclerosis depend on the specific type and severity of the condition, and may include medications, physical therapy, and lifestyle modifications.

Examples of acute diseases include:

1. Common cold and flu
2. Pneumonia and bronchitis
3. Appendicitis and other abdominal emergencies
4. Heart attacks and strokes
5. Asthma attacks and allergic reactions
6. Skin infections and cellulitis
7. Urinary tract infections
8. Sinusitis and meningitis
9. Gastroenteritis and food poisoning
10. Sprains, strains, and fractures.

Acute diseases can be treated effectively with antibiotics, medications, or other therapies. However, if left untreated, they can lead to chronic conditions or complications that may require long-term care. Therefore, it is important to seek medical attention promptly if symptoms persist or worsen over time.

... , sold under the brand name Capoten among others, is an angiotensin-converting enzyme (ACE) inhibitor used for the ... Brown NJ, Vaughan DE (April 1998). "Angiotensin-converting enzyme inhibitors". Circulation. 97 (14): 1411-1420. doi:10.1161/01. ... "Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents". Science. ... "High-resolution crystal structures of Drosophila melanogaster angiotensin-converting enzyme in complex with novel inhibitors ...
Khan MG (2015). "Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers". Cardiac Drug Therapy. New York ... Lisinopril is an ACE inhibitor, meaning it blocks the actions of angiotensin-converting enzyme (ACE) in the renin-angiotensin- ... Lisinopril is a medication of the angiotensin-converting enzyme (ACE) inhibitor and is used to treat high blood pressure, heart ... Menard J, Patchett AA (2001). Richards FM, Eisenberg DS, and Kim PS (eds.). "Angiotensin-converting enzyme inhibitors". ...
ACE inhibitors Angiotensin-converting enzyme 2 (ACE2) Hypotensive transfusion reaction Renin-angiotensin system GRCh38: Ensembl ... Proteopedia Angiotensin-converting_enzyme - the Angiotensin-Converting Enzyme Structure in Interactive 3D Angiotensin+ ... peptidase P dipeptide hydrolase peptidyl dipeptidase angiotensin converting enzyme kininase II angiotensin I-converting enzyme ... 2013-01-01). "Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of ...
"The future of angiotensin-converting enzyme inhibitors". Journal of Cardiovascular Pharmacology. 7 Suppl 1: S30-34. doi:10.1097 ... While at Squibb, the FDA had denied a license to the first ACE inhibitor, captopril, due the side effects being too ... His last publication before retirement was a review article on ACE inhibitors. Following retirement in 1985, he moved to ... where he played an important part in getting the first ACE inhibitor, captopril, licensed. George Bellamy Mackaness was born on ...
"Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor ... Sabroe RA, Black AK (February 1997). "Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema". British Journal of ... Israili ZH, Hall WD (August 1, 1992). "Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor ... Dykewicz, MS (August 2004). "Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms ...
It is in the angiotensin-converting-enzyme (ACE) inhibitor family of medications. Enalapril was patented in 1978, and came into ... Normally, angiotensin I is converted to angiotensin II by an angiotensin-converting enzyme (ACE). Angiotensin II constricts ... Menard J and Patchett A. Angiotensin-Converting Enzyme Inhibitors. Pp 14-76 in Drug Discovery and Design. Volume 56 of Advances ... Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta- ...
February 2015). "Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a ... "Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors". American Journal of Health-System ... HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a ... It is an inhibitor of the protein kallikrein and a 60-amino acid polypeptide which was developed from a Kunitz domain through ...
It is an angiotensin converting enzyme inhibitor (ACE inhibitor) which inhibits the conversion of angiotensin I to angiotensin ... It was found that teprotide inhibits the enzyme that converts angiotensin I to angiotensin II. From this researchers conducted ... "Angiotensin-converting enzyme inhibitors from the venom of bothrops jararaca. Isolation, elucidation of structure, and ... "History of the design of captopril and related inhibitors of angiotensin converting enzyme". Hypertension. 17 (4): 589-592. doi ...
1982), "Angiotensin-Converting Enzyme Inhibitors: Importance of the Amide Carbonyl of Mercaptoacyl Amino Acids for Hydrogen ... 1980), "A new class of angiotensin-converting enzyme inhibitors", Nature, 288 (5788): 280-283, Bibcode:1980Natur.288..280P, doi ... "Silanediol Inhibitors of Angiotensin-Converting Enzyme. Synthesis and Evaluation of Four Diastereomers of Phe[Si]Ala Dipeptide ... "Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents.", Science, ...
Angiotensin-converting-enzyme inhibitors, or ACE inhibitors, are a class of widely-prescribed medications used in hypertension ... Sweitzer, Nancy K. (2003). "What Is an Angiotensin Converting Enzyme Inhibitor?". Circulation. 108 (3): e16-18. doi:10.1161/01. ... as have small peptides that inhibit angiotensin-1-converting enzyme; the venom of the redback, although little-studied, likely ... It contains a complex mixture of cellular constituents, enzymes and a number of high-molecular-weight toxins, including insect ...
Ondetti started work on the isolation of angiotensin-converting enzyme inhibitors. By 1973, work on ACE inhibitors stopped ... Ondetti M A, Rubin B, Cushman D W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active ... Ondetti M A, Sabo E F. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of ... In 1974, Ondetti resumed unofficial work on ACE inhibitors with strong resolve, "We said this was the thing that we had to do ...
However, Angiotensin converting enzyme inhibitors and Angiotensin II receptor antagonists are favoured due to their anti- ... Importantly, angiotensin-converting enzyme inhibitors were used in both groups equally.[citation needed] Cyclophosphamide ( ...
"Treatment of hypertension in black patients with angiotensin-converting enzyme inhibitors". Journal of the National Medical ...
Finley, PR (February 1996). "Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction". J ... ACE inhibitors have also been shown in a retrospective case-control study to increase lithium concentrations. This is likely ... Another possible mechanism is that ACE inhibitors can lead to a decrease in sodium and water. This will increase lithium ... Lithium concentrations can also be increased with concurrent use of ACE inhibitors such as captopril, enalapril, and lisinopril ...
These include the angiotensin-converting enzyme inhibitor captopril. Captopril is based on the peptidic bradykinin potentiating ... Enzymes in turn are composed of amino acids and often non-peptidic cofactors that are essential for enzyme function. The basic ... In animals, the three carbon precursors lactate or glycerol can be converted into pyruvate which in turn can be converted into ... they possess enzymes that are functional under quite unusual conditions. These enzymes are of potential use in the food, ...
It is an angiotensin-converting enzyme (ACE) inhibitor. In small studies, zofenopril appeared significantly more effective in ... Subissi A, Evangelista S, Giachetti A (1999). "Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor ... ACE inhibitors, Carboxamides, Enantiopure drugs, Prodrugs, Pyrrolidines, All stub articles, Cardiovascular system drug stubs). ...
If the DPGN is caused by IgA nephropathy then corticosteroids, angiotensin-converting enzyme inhibitor (ACEIs), angiotensin ... "Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension". Cochrane ... ARBs block angiotensin II from acting. The patient's diet should also be changed. The patient should restrict salt intake to ... ACEIs will decrease hypertension by preventing the body from creating angiotensin II, which narrows the blood vessels. ...
While angiotensin converting enzyme (ACE) inhibitors block the cleavage of angiotensin I to angiotensin II, the active peptide ... Gales BJ, Bailey EK, Reed AN, Gales MA (February 2010). "Angiotensin-converting enzyme inhibitors and angiotensin receptor ... Li EC, Heran BS, Wright JM (August 2014). "Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers ... Bakris GL, Weir MR (March 2000). "Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a ...
Renin comes one level higher than angiotensin converting enzyme (ACE) in the renin-angiotensin system. Renin inhibitors can ... Li EC, Heran BS, Wright JM (August 2014). "Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers ... ACE inhibitors inhibit the activity of angiotensin-converting enzyme (ACE), an enzyme responsible for the conversion of ... an angiotensin converting enzyme inhibitor) or amlodipine (a calcium channel blocker). (ALLHAT showed that doxazosin, an alpha- ...
He was on an angiotensin converting enzyme inhibitor, enalapril. He presented with diarrhoea, vomiting and difficulty breathing ...
... angiotensin converting enzyme inhibitors (ACE inhibitors), and angiotensin receptor blockers (ARBs). These medications may be ... angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and renin inhibitors were developed as ... Raebel MA (June 2012). "Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor ... A subset particularly responsive to converting enzyme inhibitors". Journal of Hypertension Supplement. 3 (2): S81-87. PMID ...
Angiotensin-converting enzyme (ACE) inhibitors: Antihypertensive effect of ACE inhibitors may be diminished. Anticoagulants: ... Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase (COX-2 inhibitor) activity and ...
Angioedema can also be drug-induced (most notably, by angiotensin converting enzyme inhibitors). The underlying mechanism can ... of SJS or TEN compared to the general population and have been found to express low levels of the drug metabolizing enzyme ...
The mushroom contains nicotianamine, an ACE inhibitor (angiotensin-converting enzyme). Nicotianamine is a metal-chelating ... Izawa H, Aoyagi Y (2006). "Inhibition of angiotensin converting enzyme by mushroom". Journal of the Japanese Society for Food ...
"Intestinal Angioedema Induced by Angiotensin-Converting Enzyme Inhibitors: An Underrecognized Cause of Abdominal Pain?". The ... When the pancreas is unable to secrete digestive enzymes, such as with a pancreatic cancer occluding the pancreatic duct, ... Though less common, medications such as ACE inhibitors can cause angioedema and small bowel thickening. The small intestine ... and through blood tests such as measurement of the amylase and lipase enzymes.: 888-894 Diseases of the hepatobiliary system ...
January 2011). "Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors- ... 12S-HpETE, which is the direct precursor to HxA3 and HxB3 in the ALOX12 pathway, may act only after being converted to these ... While the earliest inhibitors, such as HC-030031, were lower potency (micromolar inhibition) and had limited TRPA1 specificity ... A number of small molecule inhibitors (antagonists) have been discovered which have been shown to block the function of TRPA1. ...
Angiotensin-converting enzyme inhibitors are indicated in individuals with diabetes, kidney disease, and hypertension. Statin ...
"Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough". ... The ability of endotoxins and IL-1β but not that of PGE2 to trigger fever is blocked by inhibitors of nitric oxide and PG2. EP3 ... Genetic polymorphism in the EP3 receptor (rs11209716), has been associated with ACE inhibitor-induce cough in humans. The use ... pathways that activate phospholipase C to convert cellular phospholipids to diacylglycerol which promotes the activation of ...
Angiotensin-converting enzyme (ACE) inhibitors can also be used to reduce glomerular filtration rate. In young babies and ...
Dykewicz, Mark S. (April 2004). "Cough and Angioedema From Angiotensin-Converting Enzyme Inhibitors: New Insights Into ... and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs". Am. J. Vet ... It is an ACE inhibitor and works by decreasing renin-angiotensin-aldosterone system activity. Benazepril was patented in 1981 ... Benazepril Hydrochloride's OCh2Ch3 group must be metabolized in order to inhibit the ACE Enzyme to form Benazeprilat, which is ...
19 because the virus accesses host cells via the receptor for the enzyme angiotensin-converting enzyme 2 (ACE2), which is most ... Theoretically, the usage of angiotensin receptor blockers (ARB) and ACE inhibitors upregulating ACE2 expression might increase ... Human angiotensin converting enzyme 2 (hACE2) is the host factor that SARS-CoV-2 virus targets causing COVID‑19. ...
Angiotensin-converting enzyme (ACE) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) are also drugs associated ... such as acid-reducing drugs like H2-receptor antagonists or proton pump inhibitors. These new drugs replaced Sippy's diet ...
... and angiotensin-converting enzyme inhibitors. Residence in an institutional setting, prolonged hospitalization or surgical ... Others: Age, male gender, diabetes mellitus, malnutrition, use of antipsychotic drugs, proton pump inhibitors, ... such as proton pump inhibitors, that decrease the acidity of the stomach, may favor the growth of bacteria and increase the ...
... angiotensin-converting enzyme inhibitor). This may occur with the class's better known side effect of dry cough (due to ...
Takase K, Ikuse T, Aono H, Okahara A (January 1995). "Toxicity study of the angiotensin converting enzyme inhibitor rentiapril ... ACE inhibitors, Carboxamides, Carboxylic acids, Enantiopure drugs, Phenols, Thiazolidines, Thiols, All stub articles, ...
Angiotensin converting enzyme inhibitors, adrenergic agents such as alpha-1 blockers and beta-blockers and alpha-2 agonists, ... antiplatelet agents (aspirin and clopidogrel), naftidrofuryl, pentoxifylline, and cilostazol (selective PDE3 inhibitor) are ...
His seminal research laid the foundation for the development of angiotensin-converting-enzyme (ACE) inhibitors, which are used ...
Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and ... T. S. Kang, L. Wang, C. N. Sarkissian, A. Gamez, C. R. Scriver and R. C. Stevens (2010) Converting an injectable protein ... the human angiotensin II receptor type 1 (AT1R), human P2Y receptor 1 (P2Y1); and the human Rhodopsin-Arrestin complex. 2016: ... However, an enthusiastic professor (John Ricci) converted him to the study of Chemistry. He spent two summers working as an ...
UK-414,495 Omapatrilat (dual inhibitor of NEP and angiotensin-converting enzyme) developed by BMS did not receive FDA approval ... Ecadotril Candoxatril Other dual inhibitors of NEP with ACE/angiotensin receptor are (in 2003) being developed by ... Inhibitors have been designed with the aim of developing analgesic and antihypertensive agents that act by preventing ... Inhibitors have been designed with the aim of developing analgesic and antihypertensive agents that act by preventing ...
Knafl, G. J., Moser, D. K., Wu, J. R., & Riegel, B. (2019). Discontinuation of angiotensin-converting enzyme inhibitors or beta ...
The enzyme catalyzes sequential hydroxylations of the steroid angular methyl group at C18 after initial 11β-hydroxylation (the ... Brown RD, Strott CA, Liddle GW (June 1972). "Site of stimulation of aldosterone biosynthesis by angiotensin and potassium". The ... Aldosterone synthase converts 11-deoxycorticosterone to corticosterone, to 18-hydroxycorticosterone, and finally to aldosterone ... Ongoing medical research is focusing on the synthesis of second-generation aldosterone synthase inhibitors to create an ideally ...
Activity of TNFα in turbulent flow was measured by the expression of TNFα-converting enzyme (TACE) in blood. TNFα decreased if ... MiR-712 targets tissue inhibitor of metalloproteinases 3 (TIMP3). TIMPs normally regulate activity of matrix metalloproteinases ... "Loss of Timp3 gene leads to abdominal aortic aneurysm formation in response to angiotensin II". The Journal of Biological ... Most commonly, enzymes known as adenosine deaminases acting on RNA (ADARs) catalyze adenosine to inosine (A to I) transitions. ...
... is a known complication of the use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II ... "Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency ... and Angiotensin-Neprilysin Inhibitor LCZ969.: 120 The angioedema appears to be dose dependent as it may resolve with decreased ... Some common ACE Inhibitors are: Benazepril (Lotensin) Captopril (Capoten) Enalapril (Vasotec) Lisinopril (Prinivil, Zestril) ...
A class of drugs called angiotensin converting enzyme inhibitors (ACE inhibitors) increase bradykinin levels by inhibiting its ... the first angiotensin converting enzyme inhibitor captopril.[citation needed] It was approved by the FDA for the treatment of ... Endothelin converting enzyme-1, Endothelin converting enzyme-2. Bradykinin is a potent endothelium-dependent vasodilator and ... Bradykinin is also thought to be the cause of the dry cough in some patients on widely prescribed angiotensin-converting enzyme ...
September-October 2017). "Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway ... in adults with C1-esterase-inhibitor deficiency. It is not effective in angioedema caused by medication from the ACE inhibitor ... Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor. Little is ...
... with neurogenic hypertension who fail in achieving blood pressure control with angiotensin converting enzyme inhibitors (ACEi ... Grapefruit is also a powerful inhibitor of the CYP3A4 enzyme, so concurrent use is not recommended as it may increase the ... Some drugs; such as Fluoxetine, Paroxetine and Ritonavir are strong inhibitors of the CYP2D6 enzyme and therefore it is not ... Co-administration of alpha-1 inhibitor can cause hypotension. Since alpha-1 blockers may cause orthostatic hypotension, co- ...
... also inhibits angiotensin converting enzyme (ACE) (an exopeptidase) Alatriopril - also inhibits ACE Daglutril - also inhibits ... Some examples of endopeptidase inhibitors include the following: Neprilysin inhibitors Selective neprilysin inhibitors ... An endopeptidase inhibitor is a drug that inhibits one or more endopeptidase enzymes. Endopeptidases are one of two types of ... inhibitor of cysteine proteases Camostat - inhibitor of trypsin and various other proteases Ecallantide - kallikrein inhibitor ...
ACE inhibitor Angiotensin conversion enzyme. A class of drugs used to decrease hypertension, mainly by interfering with the ... Sometimes called 'animal starch'. It is stored in liver and muscle cells and can be converted to glucose when needed. The ... In humans, it requires a special enzyme (lactase) for disassembly during digestion. Most humans lose this enzyme in adulthood ... Aldose reductase inhibitor Alpha cell one of the types of cell in the pancreas (in areas called the Islets of Langerhans). ...
... angiotensin converting enzyme (ACE, CD143); tissue factor TF (CD142, thromboplastin); decay accelerating factor (CD55); ... protectin (CD59, inhibitor of MAC) and complement regulatory membrane cofactor protein (CD46). Prostasomes also contain high ... Ronquist G, Frithz G, Jansson A (1988). "Prostasome membrane associated enzyme activities and semen parameters in men attending ... A possible role for Tissue Factor Pathway Inhibitor in fertility through semen liquefaction". Thrombosis and Haemostasis. 93 (5 ...
Additional labelling may be required in certain drug classes; For example, angiotensin-converting enzyme (ACE) inhibitors such ... In 2004, the utilization of cox-2 inhibitors was discouraged due to increased risks of stroke and heart attack in prolonged use ...
... protease inhibitors MeSH D27.505.519.389.745.085 - angiotensin-converting enzyme inhibitors MeSH D27.505.519.389.745.325 - ... enzyme inhibitors MeSH D27.505.519.389.099 - aromatase inhibitors MeSH D27.505.519.389.200 - carbonic anhydrase inhibitors MeSH ... trypsin inhibitors MeSH D27.505.519.389.755 - protein kinase inhibitors MeSH D27.505.519.389.760 - protein synthesis inhibitors ... integrase inhibitors MeSH D27.505.519.389.375.400 - hiv integrase inhibitors MeSH D27.505.519.389.480 - lipoxygenase inhibitors ...
... of a gut commensal that compromises the blood pressure-lowering effect of ester angiotensin-converting enzyme inhibitors. https ...
... angiotensin converting enzyme [ACE] inhibitors, Angiotensin II receptor antagonist), cholesterol-lowering agents (niacin, ... Proton pump inhibitors (PPIs) were found to be better than placebo in a literature review, especially when looking at long-term ... It is often treated with proton pump inhibitors. If left untreated, the chronic damage to the esophageal tissues poses a risk ... "Proton Pump Inhibitors: Use in Adults" (PDF). Centers for Medicare & Medicaid Services. 2015. Retrieved 2022-01-27. Heiran, ...
... preferably with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Unfortunately, these ... May induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, does not affect the response to ... Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion. ... Nonpeptide angiotensin II receptor antagonist that blocks the vasoconstricting and aldosterone-secreting effects of angiotensin ...
... preferably with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Unfortunately, these ... May induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, does not affect the response to ... Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion. ... Nonpeptide angiotensin II receptor antagonist that blocks the vasoconstricting and aldosterone-secreting effects of angiotensin ...
Angiotensin-converting enzyme inhibitors (ACEIs) are effective antihypertensive drugs, but use of ACEIs during the second and ... Postmarketing Surveillance for Angiotensin-Converting Enzyme Inhibitor Use During the First Trimester of Pregnancy -- United ... Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med 1993;118:643-4. ... TABLE 1. Pregnancy outcome based on timing of exposure to angiotensin-converting enzyme inhibitors (ACEIs), by week of last ...
Current Respiratory Medicine Reviews Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II ... Title: Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers ... Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in ... Molteni Agostino, Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor ...
angiotensin converting enzyme inhibitors. Definitions. Medical Information Search ... Angiotensin IIAngiotensin-Converting Enzyme InhibitorsReceptor, Angiotensin, Type 1Receptors, AngiotensinReceptor, Angiotensin ... Angiotensin IIAngiotensin-Converting Enzyme InhibitorsReceptor, Angiotensin, Type 1Receptors, AngiotensinReceptor, Angiotensin ... Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an ...
Angiotensin Converting Enzyme Inhibitors can be used in whic…. Written by Anonymous on June 16, 2021 in Uncategorized with no ... Angiоtensin Cоnverting Enzyme Inhibitоrs cаn be used in which of the following conditions? 1. hypertension 2. & ... Angiоtensin Cоnverting Enzyme Inhibitоrs cаn be used in which of the following conditions? 1. hypertension 2. & ...
The willingness to pay (WTP) of the Japanese public for OTC imidapril, an angiotensin-converting enzyme (ACE) inhibitor, as a ... The willingness to pay (WTP) of the Japanese public for OTC imidapril, an angiotensin-converting enzyme (ACE) inhibitor, as a ... The willingness to pay (WTP) of the Japanese public for OTC imidapril, an angiotensin-converting enzyme (ACE) inhibitor, as a ... The willingness to pay (WTP) of the Japanese public for OTC imidapril, an angiotensin-converting enzyme (ACE) inhibitor, as a ...
Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of ... angiotensin II receptor blockers; angiotensin-converting enzyme inhibitors; coronavirus infections; severe acute respiratory ... We searched for randomized trials evaluating the effect of angiotensin-converting enzyme inhibitors or angiotensin II receptor ... Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19 ...
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta- ... Angiotensin-converting enzyme (ACE) inhibitors and ACE-receptor blockers (ARB). Trials examining the incidence of AF in ... Experimental and clinical data suggest that renin-angiotensin system (RAS) antagonists and HMG-CoA-reductase inhibitors ( ... Experimental and clinical data suggest that renin-angiotensin system (RAS) antagonists and HMG-CoA reductase inhibitors ( ...
Angiotensin converting enzyme inhibitors in congestive heart failure: Overview in comparison of captopril and enalapril. The ... Angiotensin converting enzyme inhibitors in congestive heart failure: Overview in comparison of captopril and enalapril. / ... T1 - Angiotensin converting enzyme inhibitors in congestive heart failure. T2 - Overview in comparison of captopril and ... Angiotensin converting enzyme inhibitors in congestive heart failure: Overview in comparison of captopril and enalapril. ...
Chronic hyperplastic laryngitis following treatment of hypertension with angiotensin converting enzyme-inhibitor].. M Fuchs, M ... Although hoarseness is documented as a potential side effect of angiotensin converting enzyme-inhibitors, morphological ... old patient who developed chronic hyperplastic laryngitis during treatment with the angiotensin converting enzyme-inhibitor ... Cotransporter 2 Inhibitors for the. Treatment of Patients With Heart. Failure. Importance: Only 1 class of glucose-lowering ...
Endogenous Inhibitors and Secretion in the Serum, Lungs and Heart. ... Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational ... Human Tissue Angiotensin Converting Enzyme (ACE) Activity Is Regulated by Genetic Polymorphisms, Posttranslational ...
Posted in Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non- ... Category: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non- ... Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic ... Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic ...
A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. In: New ... A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New ... A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. / Wing, ... Dive into the research topics of A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for ...
... a discussion of the current understanding of the chemical structures and the modes of action of angiotensin converting enzyme ( ... ACE) inhibitors and angiotensin receptor (ATR) antagonists, review includes their SAR analysis and chemical ... The renin-angiotensin system (RAS) plays an important role in pathogenesis of hypertension, congestive heart failure, and ... HISTORICAL OVERVIEW, DEVELOPMENT AND NEW APPROACHES IN DESIGN OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN ...
angiotensin converting enzyme inhibitors, such as lisinopril. *angiotensin receptor blockers, such as irbesartan ... using an SGLT2 inhibitor, such as Invokana, as part of the medication regimen for controlling blood sugar in adults with type 2 ... other SGLT2 inhibitors, such as empagliflozin (Jardiance). *glucagon-like peptide-1 (GLP-1) receptor agonists, such as ... It belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT-2) inhibitors. (A drug class describes a group of ...
Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer Objectives: ... Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are the most commonly prescribed ...
The effects of angiotensin converting enzyme inhibitor spirapril on vascular distensibility in normotensive and spontaneously ...
Underdosing of angiotensin-converting-enzyme inhibitors, initial encounter. T465X6A. Underdosing of other antihypertensive ... Underdosing of selective serotonin and norepinephrine reuptake inhibitors, initial encounter. T43226A. Underdosing of selective ... Underdosing of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter. T503X6A. Underdosing of ... Underdosing of monoamine-oxidase-inhibitor antidepressants, initial encounter. T43206A. Underdosing of unspecified ...
... inhibitors improve left ventricular (LV) remodelling and outcome in heart failure and hypertensive heart disease. They may be ... AIMS: Angiotensin-converting enzyme (ACE) inhibitors improve left ventricular (LV) remodelling and outcome in heart failure and ... A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic ... A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic ...
Taking precautions with angiotensin converting enzyme inhibitors. Screening for unilateral renal artery stenosis cannot be ... Worsening renal function with angiotensin-converting enzyme inhibitors (ACEi) and a systolic/ diastolic abdominal bruit point ... and develop deterioration of renal function after taking angiotensin-converting enzyme (ACE) inhibiting drugs. Ultrasound renal ... Anti-depressants: Monoamine oxidase inhibitors, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors ...
HMG CoA reductase inhibitors, fibrates, imidazole, benzimidazole and triazole derivatives, corticosteroids, glucocorticoids, ... for angiotensin-converting enzyme (ACE) inhibitors (Mastrobattista, 1997), angiotensin type 1 (AT1) receptor antagonists ( ... Mastrobattista, J. M. (1997). Angiotensin converting enzyme inhibitors in pregnancy. Semin. Perinatol. 21, 124-134. doi: ... Hinsberger, A., Wingen, A. M., and Hoyer, P. F. (2001). Angiotensin-II-receptor inhibitors in pregnancy. Lancet 357, 1620. doi ...
Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular ... who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting or at ...
Celecoxib belongs to the group of medications called selective COX-2 inhibitors, which is a kind of nonsteroidal anti- ... angiotensin-converting enzyme inhibitors (ACEIs; e.g., captopril, enalapril, ramipril). *angiotensin II receptor blockers (ARBs ... Celecoxib belongs to the group of medications called selective COX-2 inhibitors, which is a kind of nonsteroidal anti- ... Heart attack and stroke: The use of selective COX-2 inhibitor NSAIDs, including celecoxib, is associated with an increased risk ...
angiotensin converting enzyme inhibitors (ACEIs; captopril, ramipril) *angiotensin receptor blockers (ARBs; e.g., candasartan, ... monoamine oxidase inhibitors (MAOIs; e.g., moclobemide, rasagiline, selegiline, tranylcypromine). *muscle relaxants (e.g., ... selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, fluoxetine, paroxetine, sertraline). *serotonin antagonists ( ... HIV non-nucleoside reverse transcriptase inhibitors (e.g., delavirdine, efavirenz, etravirine, nevirapine) ...
Angiotensin-converting Enzyme (ACE) Inhibitors. *Angiotensin II Receptor Antagonists (ARBs). *Diuretics. *Others ... with diabetes and hypertension who have proteinuria may require blood pressure medication such as angiotensin-converting enzyme ... Iptocan is a first-in-class, oral, targeted factor B inhibitor, which also showed a stabilizing kidney function in patients ... BENLYSTA, a BLyS-specific inhibitor, is a human monoclonal antibody that binds to soluble BLyS. These factors are expected to ...
Benazepril is an angiotensin-converting enzyme (ACE) inhibitor. It works by blocking a substance in the body that causes the ...
Angiotensin-converting enzyme (ACE) inhibitors are a common treatment for high blood pressure. They help your body make less of ... In rare cases, ACE inhibitors make it harder for air to flow through your body if you have asthma. ... ACE inhibitors lower your blood pressure after the blood vessels open and relax. ... something called angiotensin, a chemical which causes your arteries to narrow. ...
angiotensin-converting enzyme inhibitors. *statins.. The benefits of these interventions are largely independent, but when used ...
  • Angiotensin-converting enzyme inhibitors (ACEIs) are effective antihypertensive drugs, but use of ACEIs during the second and third trimesters of pregnancy has been associated with a pattern of defects known as ACEI fetopathy. (cdc.gov)
  • SARS-CoV-2 accesses host cells via angiotensin -converting enzyme -2, which is also affected by commonly used angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), raising concerns that ACEI or ARB exposure may portend differential COVID-19 outcomes. (bvsalud.org)
  • ACE inhibitors (ACEIs) are widely used for the management of hypertension. (nih.gov)
  • Objectives: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are the most commonly prescribed antihypertensives, with prior studies identifying a possible association between long-term use and increased rates of lung cancer. (sma.org)
  • Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in lower aldosterone secretion. (medscape.com)
  • It is converted to angiotensin II , a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. (lookformedical.com)
  • Angiotensin converting enzyme (ACE) converts Angiotensin I to a potent vasoconstrictor angiotensin II (ANG II). (nih.gov)
  • The general approach to therapy of ischemic nephropathy involves control of hypertension, preferably with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). (medscape.com)
  • Useful for hypertension and heart failure in patients who are intolerant of ACE inhibitors. (medscape.com)
  • The ACE inhibitors are considered first line drugs for the therapy of hypertension and are considered particularly helpful in preventing the renal complications of diabetes and high blood pressure. (nih.gov)
  • Preventive therapy by angiotensin-converting enzyme (ACE) inhibitors is considered in hypertension and, more recently, in chronic heart failure. (ox.ac.uk)
  • To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II , patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS . (lookformedical.com)
  • An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE . (lookformedical.com)
  • Chronic hyperplastic laryngitis following treatment of hypertension with angiotensin converting enzyme-inhibitor]. (qxmd.com)
  • We compared the outcomes in older subjects with hypertension who were treated with angiotensin-converting-enzyme (ACE) inhibitors with the outcomes in those treated with diuretic agents. (edu.au)
  • We compared the outcomes in older subjects with hypertension who were treated with angiotensin-converting-enzyme (ACE) inhibitors with the outcomes in those treated with diuretic agents.METHODS:We conducted a prospective, randomized, open-label study with blinded assessment of end points in 6083 subjects with hypertension who were 65 to 84 years of age and received health care at 1594 family practices. (edu.au)
  • The renin-angiotensin system (RAS) plays an important role in pathogenesis of hypertension, congestive heart failure, and chronic renal failure. (ijpsr.com)
  • Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (lookformedical.com)
  • Levine, TB, Olivari, MT & Cohn, JN 1986, ' Angiotensin converting enzyme inhibitors in congestive heart failure: Overview in comparison of captopril and enalapril ', The American Journal of Medicine , vol. 81, no. 4 SUPPL. (umn.edu)
  • Cohn, Jay N. / Angiotensin converting enzyme inhibitors in congestive heart failure : Overview in comparison of captopril and enalapril . (umn.edu)
  • 4. Reliability of captopril renography in patients under chronic therapy with angiotensin II (AT1) receptor antagonists. (nih.gov)
  • May induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, does not affect the response to bradykinin, and is less likely to be associated with cough and angioedema. (medscape.com)
  • The angiotensin-converting enzyme (ACE) inhibitors are a widely used class of antihypertensive medications that act by blocking the conversion of angiotensin I to angiotensin II, thus inhibiting an intermediate step in the renin-angiotensin pathway. (nih.gov)
  • The ACE inhibitors act by blocking the conversion of angiotensin I to angiotensin II, the active peptide that causes the vasoconstriction and sodium retention induced by activation of the renin-angiotensin pathway. (nih.gov)
  • On the other hand, local renin-angiotensin systems may control growth processes both in myocardial and in smooth muscle cells. (ox.ac.uk)
  • They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system . (lookformedical.com)
  • A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN , leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM . (lookformedical.com)
  • All components of the renin-angiotensin system (RAS) have also been identified in the brain. (nih.gov)
  • Although both drugs act on the renin-angiotensin system via converting enzyme inhibition, their different chemical structures may dispose them to different pharmacologic and physiologic activity. (umn.edu)
  • It has been postulated that agents that inhibit the renin-angiotensin system confer benefit beyond the reduction of blood pressure alone. (edu.au)
  • 2. ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis. (nih.gov)
  • ACE-inhibitors are reliable antihypertensive drugs and may have additional specific effects on the heart and vascular smooth muscle. (ox.ac.uk)
  • Major chemical compound groups identified to cause glomerular and tubular alterations included dihydropyridine derivatives, HMG CoA reductase inhibitors, fibrates, imidazole, benzimidazole and triazole derivatives, corticosteroids, glucocorticoids, acetic acid derivatives and propionic acid derivatives. (frontiersin.org)
  • A new indication, therefore, for ACE-inhibitors could be left ventricular dysfunction after myocardial infarction. (ox.ac.uk)
  • Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. (nih.gov)
  • The rates of nonfatal cardiovascular events and myocardial infarctions decreased with ACE-inhibitor treatment, whereas a similar number of strokes occurred in each group (although there were more fatal strokes in the ACE-inhibitor group). (edu.au)
  • These features may be related to fetal hypotension secondary to ACEI-induced decreases in fetal angiotensin or increased bradykinin (1,2). (cdc.gov)
  • Angiotensin-converting enzyme also breaks down BRADYKININ , a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. (lookformedical.com)
  • To conduct a trial to test the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy. (nih.gov)
  • AIMS: Angiotensin-converting enzyme (ACE) inhibitors improve left ventricular (LV) remodelling and outcome in heart failure and hypertensive heart disease. (ox.ac.uk)
  • 3. Can exercise renography be an alternative to ACE inhibitor renography in hypertensive patients who are suspicious for renal artery stenosis? (nih.gov)
  • A study by Bianchi et al suggested that statins, in addition to ACE inhibitors and ARBs, may reduce proteinuria and slow the progression of kidney disease. (medscape.com)
  • Nonpeptide angiotensin II receptor antagonist that blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II. (medscape.com)
  • Nowadays different modeling strategies are underway to develop tailor made molecules with the best of properties among nonpeptide renin inhibitors, dual action receptor antagonists ( e.g. angiotensin and endothelin antagonists, ACE/NEP inhibitors, AT 1 /TxA 2 antagonists, balanced AT 1 /AT 2 antagonists), triple inhibitors. (ijpsr.com)
  • ACE inhibitors are sometimes used even in patients with relatively normal blood pressure for treatment of heart failure and prevention of diabetic neuropathy. (nih.gov)
  • It remains unclear 1) what could be the adequate diagnostic procedures to identify patients for preventive treatment, 2) when therapy should be started, 3) about the duration of therapy, 4) about the doses of ACE-inhibitors for this indication, 5) what will be the side-effects when used in a broader population, and 6) will this prevention of heart failure be a specific effect of ACE-inhibitors? (ox.ac.uk)
  • Objective : To measure the value of OTC imidapril as a health care-related item by investigating the public's WTP as self-medication for primary prevention of stroke, assuming that ACE inhibitors are switched from prescription-only to OTC status. (elsevier.com)
  • 12. [Correlation of 99mTc-dTPA renal scintigraphy with ACE inhibitor and ultrasound findings in screening for renal artery stenosis]. (nih.gov)
  • An angiotensin receptor subtype that is expressed at high levels in fetal tissues. (lookformedical.com)
  • All of the currently used ACE inhibitors are associated with a low rate of serum enzyme elevations during chronic therapy (0.2% to 2%) which is minimally different from the rate of elevations during placebo therapy. (nih.gov)
  • Although hoarseness is documented as a potential side effect of angiotensin converting enzyme-inhibitors, morphological alterations in the vocal cords have not been linked to this type of drug. (qxmd.com)
  • Renin , an enzyme produced in the kidney , acts on angiotensinogen , an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I . Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II , an extremely powerful vasoconstrictor. (lookformedical.com)
  • These studies showed that ACE-inhibitors could prevent the incidence of heart failure in about one-third of patients with severe left ventricular dysfunction during 3 years of observation when compared with placebo treated patients. (ox.ac.uk)
  • Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. (nih.gov)
  • We undertook a prospective systematic overview based on data from individual patients from five long-term randomised trials that assessed inhibitors of angiotensin-converting enzyme (ACE) in patients with left-ventricular dysfunction or heart failure. (nih.gov)
  • Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure . (lookformedical.com)
  • ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure. (nih.gov)
  • In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. (nih.gov)
  • Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR. (lookformedical.com)
  • Converting prescription drugs to over-the-ounter (OTC) drugs would appear to be one solution to cut expenditure. (elsevier.com)
  • Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab. (bvsalud.org)
  • Initiation of antihypertensive treatment involving ACE inhibitors in older subjects, particularly men, appears to lead to better outcomes than treatment with diuretic agents, despite similar reductions of blood pressure. (edu.au)
  • These medications have identical beneficial effects on the kidney compared to the ACE inhibitors. (nih.gov)
  • Celecoxib belongs to the group of medications called selective COX-2 inhibitors, which is a kind of nonsteroidal anti-inflammatory drug (NSAID). (medbroadcast.com)
  • Some medications (e.g., angiotensin-converting enzyme (ACE) inhibitors) [NHLBI 2007]. (cdc.gov)
  • An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY , the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. (lookformedical.com)
  • In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney . (lookformedical.com)
  • For patients unable to tolerate ACE inhibitors. (medscape.com)
  • In addition to a discussion of the current understanding of the chemical structures and the modes of action of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor (ATR) antagonists, review includes their SAR analysis and chemical modification for improving their activity. (ijpsr.com)
  • The ACE inhibitors are rare causes of clinically apparent liver injury. (nih.gov)
  • Many effects of the angiotensin type 2 receptor such as VASODILATION and sodium loss are the opposite of that of the ANGIOTENSIN TYPE 1 RECEPTOR. (lookformedical.com)
  • Angiotensin I converting enzyme has been nominated as a potential target for AD. (nih.gov)
  • Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention. (lookformedical.com)
  • An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II . (lookformedical.com)
  • In the first part is given an overview of various ACE inhibitors. (ijpsr.com)
  • The second part is devoted to overview of angiotensin receptor antagonists. (ijpsr.com)
  • Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. (lookformedical.com)
  • This may be another site of action for ACE-inhibitors. (ox.ac.uk)
  • A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A . It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II , a vasoconstrictor and important regulator of arterial blood pressure . (lookformedical.com)
  • We report the case of a 42 year old patient who developed chronic hyperplastic laryngitis during treatment with the angiotensin converting enzyme-inhibitor Cibacen 10. (qxmd.com)